PharMerica 10-Q 6 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 31, 2014
Document Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Entity Registrant Name	'PHARMERICA CORP	'
Entity Central Index Key	'0001388195	'
Current Fiscal Year End Date	'--12-31	'
Entity Well-known Seasoned Issuer	'No	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	32,720,327

CONDENSED_CONSOLIDATED_INCOME_

CONDENSED CONSOLIDATED INCOME STATEMENTS (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
CONDENSED CONSOLIDATED INCOME STATEMENTS (Unaudited) [Abstract]	'	'	'	'
Revenues	$470.20	$436.80	$1,371	$1,307.40
Cost of goods sold	387.2	357.6	1,126.10	1,061.30
Gross profit	83	79.2	244.9	246.1
Selling, general and administrative expenses	56	55.5	171.1	167.7
Amortization expense	4.9	3.7	13.6	11.7
Merger, acquisition, integration costs and other charges	3.8	1.1	10.3	6.6
Settlement, litigation and other related charges	1.1	17.2	28.9	17.4
Restructuring costs	0.1	1	3.2	1
Write off of Deferred Debt Issuance Cost	4.3	0	4.3	0
Hurricane Sandy disaster costs	0	0.1	0.1	-0.2
Operating income	17.1	0.6	17.7	41.9
Interest expense, net	2.1	2.6	6.9	8.1
Income before income taxes	10.7	-2	6.5	33.8
Provision for income taxes	2.2	4.2	2.9	19.3
Net income	$8.50	($6.20)	$3.60	$14.50
Earnings per common share:	'	'	'	'
Basic (in dollars per share)	$0.28	($0.21)	$0.12	$0.49
Diluted (in dollars per share)	$0.28	($0.21)	$0.12	$0.48
Shares used in computing earnings per common share:	'	'	'	'
Basic (in shares)	30,073,133	29,655,201	29,944,875	29,645,380
Diluted (in shares)	30,595,302	29,655,201	30,502,928	29,950,379

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$7.10	$24.20
Accounts receivable, net	213.7	199.4
Inventory	133.4	110.2
Deferred tax assets, net	38.5	36.9
Income tax receivable	3.4	1.9
Prepaids and other assets	70	38.8
Total current assets	466.1	411.4
Equipment and leasehold improvements	190.6	179.4
Accumulated depreciation	-120.3	-117.6
Total Equipment and leasehold improvements	70.3	61.8
Goodwill	321.5	282
Intangible assets, net	184.1	136.3
Other	3.5	9.3
Total assets	1,045.50	900.8
Current liabilities:	'	'
Accounts payable	75.5	78.8
Salaries, wages and other compensation	37.3	38.7
Current portion of long-term debt	2.8	12.5
Other accrued liabilities	16.8	21
Total current liabilities	132.4	151
Long-term debt	358.1	218.8
Other long-term liabilities	72.4	49.8
Deferred tax liabilities	9.9	18.7
Commitments and contingencies (See Note 5)	'	'
Stockholders' equity:	'	'
Preferred stock, $0.01 par value per share; 1,000,000 shares authorized and no shares issued, December 31, 2013 and September 30, 2014	0	0
Common stock, $0.01 par value per share; 175,000,000 shares authorized; 31,954,264 and 32,720,327 shares issued as of December 31, 2013 and September 30, 2014, respectively	0.3	0.3
Capital in excess of par value	391.9	380.2
Retained earnings	113.8	110.2
Treasury stock at cost, 2,416,971 and 2,617,305 shares at December 31, 2013 and September 30, 2014, respectively	-33.3	'
Total stockholders' equity	472.7	462.5
Total liabilities and stockholders' equity	$1,045.50	$900.80

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) [Abstract]	'	'
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized (in shares)	175,000,000	175,000,000
Common stock, shares issued (in shares)	32,720,327	31,954,264
Treasury stock at cost, shares (in shares)	2,617,305	2,416,971

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Cash flows provided by (used in) operating activities:	'	'	'	'
Net income (loss)	$8.50	($6.20)	$3.60	$14.50
Adjustments to reconcile net income to net cash provided by (used in) operating activities:	'	'	'	'
Depreciation	4.9	4.9	14.5	14.5
Amortization	4.9	3.7	13.6	11.7
Merger, acquisition, integration costs and other charges	0	0	2.5	0
Hurricane Sandy disaster costs	0	1.8	0	0.2
Stock-based compensation and deferred compensation	1.8	2.4	5.7	6.4
Amortization of deferred financing fees	0.5	0.6	1.8	1.6
Deferred income taxes	-4	3.5	-3.3	6.4
Loss (gain) on disposition of equipment	0	0.4	-0.1	0.3
Loss (gain) on acquisition/disposition	0.1	0	-0.2	0
Loss on extinguishment of debt	4.3	0	4.3	0
Other	0	-0.2	0.1	0.1
Change in operating assets and liabilities:	'	'	'	'
Accounts receivable, net	-1.7	4.5	10.4	14.8
Inventory	14.9	42.9	-16.3	65.4
Prepaids and other assets	-15.1	-1.3	-26.2	-0.3
Accounts payable	-2.4	11.7	-22.9	3.8
Salaries, wages and other compensation	5.2	-4.5	-2.7	-7.2
Other accrued liabilities	-5.7	18.7	16.6	18.9
Change in income taxes payable (receivable)	3.7	-4.8	-0.4	1.3
Excess tax benefit from stock-based compensation	-0.2	0	-3.4	-0.4
Net cash provided by (used in) operating activities	19.7	78.1	-2.4	152
Cash flows provided by (used in) investing activities:	'	'	'	'
Purchase of equipment and leasehold improvements	-6.2	-6.9	-19	-20.9
Acquisitions, net of cash acquired	-107.2	-4.1	-124.8	-4.6
Cash proceeds from the sale of assets	0	0	0.1	0.1
Cash proceeds from dispositions	0	0	0.4	0
Net cash used in investing activities	-113.4	-11	-143.3	-25.4
Cash flows provided by (used in) financing activities:	'	'	'	'
Repayments of long-term debt	-225	-3.1	-231.3	-9.4
Borrowings of long-term debt	225	0	225	0
Net activity of long-term revolving credit facility	92	-19.6	135.9	-71.7
Payments of Debt Issuance Costs	-2.7	0	-2.7	0
Issuance of common stock	0.4	0	3.4	0.4
Treasury stock at cost	-0.2	-4.4	-5.1	-6.3
Excess tax benefit from stock-based compensation	0.2	0	3.4	0.4
Other	0	0.1	0	0.1
Net cash (used in) provided by financing activities	89.7	-27	128.6	-86.5
Change in cash and cash equivalents	-4	40.1	-17.1	40.1
Cash and cash equivalents at beginning of period	11.1	12.3	24.2	12.3
Cash and cash equivalents at end of period	7.1	52.4	7.1	52.4
Supplemental information:	'	'	'	'
Cash paid for interest	1.9	2	5.6	6.6
Cash paid for taxes	$1	$5.50	$5.70	$11.90

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) (USD $)	Common Stock [Member]	Capital in Excess of Par Value [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Total
In Millions, except Share data
Beginning Balance at Dec. 31, 2013	$0.30	$380.20	$110.20	($28.20)	$462.50
Beginning Balance (in shares) at Dec. 31, 2013	29,537,293	'	'	'	'
Net income (loss)	'	'	3.6	'	3.6
Exercise of stock options and tax components of stock-based awards, net (in shares)	278,350	'	'	'	'
Exercise of stock options and tax components of stock-based awards, net	0	6.4	0	0	6.4
Vested restricted stock units (in shares)	288,076	'	'	'	'
Vested restricted stock units	0	0	0	0	0
Vested performance stock units	0	0	0	0	0
Treasury stock at cost (in shares)	-200,334	'	'	'	'
Treasury stock at cost, value	0	0	0	-5.1	-5.1
Stock-based compensation - non-vested restricted stock	0	4.8	0	0	4.8
Stock-based compensation - stock options	0	0.5	0	0	0.5
Ending Balance at Sep. 30, 2014	0.3	391.9	113.8	-33.3	472.7
Ending Balance (in shares) at Sep. 30, 2014	30,103,022	'	'	'	'
Beginning Balance at Jun. 30, 2014	'	'	'	'	'
Net income (loss)	'	'	'	'	8.5
Vested performance stock units (in shares)	199,637	'	'	'	'
Ending Balance at Sep. 30, 2014	$0.30	'	'	'	$472.70
Ending Balance (in shares) at Sep. 30, 2014	30,103,022	'	'	'	'

ORGANIZATION_AND_SUMMARY_OF_SI

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2014
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	Nature of Business
	PharMerica Corporation (together with its subsidiaries, the "Corporation") is a pharmacy services company that services healthcare facilities, provides pharmacy management services to hospitals, provides specialty infusion services to patients outside a hospital setting, and offers the only national oncology pharmacy in the United States. The Corporation is the second largest institutional pharmacy services company in the United States based on revenues and customer licensed beds under contract, operating 104 institutional pharmacies, 14 specialty infusion pharmacies, and 5 specialty oncology pharmacies in 45 states. The Corporation's customers are typically institutional healthcare providers, such as skilled nursing facilities, nursing centers, assisted living facilities, hospitals, individuals receiving in-home care and other long-term alternative care providers. The Corporation is generally the primary source of supply of pharmaceuticals to its customers. The Corporation also provides pharmacy management services to 89 hospitals in the United States.
	Operating Segments
	The Corporation consists of three operating segments: institutional pharmacy, specialty infusion services and specialty oncology pharmacy. Management believes the nature of the products and services are similar, the payers for the products and services are common among the segments and all segments operate in the healthcare regulatory environment. In addition, the segments are economically similar. Accordingly, management has aggregated the three operating segments into one reporting segment.
	Principles of Consolidation
	All intercompany transactions have been eliminated.
	Basis of Presentation
	The accompanying condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X and do not include all of the information and disclosures required by generally accepted accounting principles in the United States ("U.S. GAAP") for complete financial statements. Accordingly, the accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements of the Corporation and related footnotes for the year ended December 31, 2013, included in the Corporation's Annual Report on Form 10-K. The balance sheet as of December 31, 2013 has been derived from the audited consolidated financial statements adjusted for acquisition related measurement period adjustments.
	The results of operations for the interim periods are not necessarily indicative of results of operations for a full year. It is the opinion of management that all necessary adjustments for a fair presentation of the condensed consolidated financial statements for the interim periods have been made and are of a normal recurring nature.
	Use of Estimates
	The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP which requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates are involved in collectability of accounts receivable, revenue recognition, inventory valuation, supplier rebates, the valuation of long-lived assets and goodwill, and accounting for income taxes. Actual amounts may differ from these estimates.
	Fair Value of Financial Instruments
	Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based upon assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Corporation follows a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	Level 1:	Observable inputs such as quoted prices in active markets;
	Level 2:	Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and
	Level 3:	Unobservable inputs for which there is little or no market data, which require the Corporation to develop its own assumptions.
	NOTE 1—ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
	Assets and liabilities measured at fair value are based on one or more of the following three valuation techniques:
		A.	Market approach: Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.
		B.	Cost approach: Amount that would be required to replace the service capacity of an asset (replacement cost).
		C.	Income approach: Techniques to convert future amounts to a single present amount based upon market expectations (including present value techniques, option-pricing and excess earnings models).
	The financial liabilities recorded at fair value at December 31, 2013 and September 30, 2014 are set forth in the tables below (dollars in millions):
	As of December 31, 2013	Asset/(Liability)				Level 1				Level 2				Level 3				Valuation
																		Technique
	Financial Liabilities
	Deferred Compensation Plan		$	(6.9	)		$	-			$	(6.9	)		$	-			A
	Contingent Consideration			(0.7	)			-				-				(0.7	)		C
	Mandatorily Redeemable Interest			(8.2	)			-				-				(8.2	)		C
	As of September 30, 2014	Asset/(Liability)				Level 1				Level 2				Level 3				Valuation
																		Technique
	Financial Liabilities
	Deferred Compensation Plan		$	(7.7	)		$	-			$	(7.7	)		$	-			A
	Contingent Consideration			(1.8	)			-				-				(1.8	)		C
	Mandatorily Redeemable Interest			(7.5	)			-				-				(7.5	)		C
	The deferred compensation plan liability represents an unfunded obligation associated with the deferred compensation plan offered to eligible employees and members of the Board of Directors of the Corporation. The fair value of the liability associated with the deferred compensation plan is derived using pricing and other relevant information for investments in phantom shares of certain available investment options, primarily mutual funds. This liability is classified as other long-term liabilities in the accompanying condensed consolidated balance sheet.
	The contingent consideration represents future earn-outs associated with the Corporation's acquisition of an institutional pharmacy business purchased in 2013 and an infusion business purchased in 2014. The fair values of the liabilities associated with the contingent consideration were derived using the income approach with unobservable inputs, which included future gross profit forecasts and present value assumptions, and there was little or no market data. The Corporation assessed the fair values of the liabilities as of the acquisition date and will assess quarterly thereafter until settlement. This liability is classified as other long-term liabilities in the accompanying condensed consolidated balance sheet.
	The mandatorily redeemable interest represents a future obligation associated with the Corporation's acquisition of a specialty pharmacy business purchased on December 6, 2013. The mandatorily redeemable interest is classified as a long-term liability and was measured at fair value as of December 31, 2013 and September 30, 2014. The fair value was derived using the income approach with unobservable inputs, which included a future gross profit forecast and present value assumptions, and there was little or no market data.
	There were no transfers between the three-tier fair value hierarchy levels during the periods presented.
	The carrying amounts reported in the accompanying condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, and accounts payable approximate fair value because of the short-term maturity of these instruments. The Corporation's debt approximates fair value due to the terms of the interest being set at variable market interest rates (Level 2).
	NOTE 1—ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable primarily consist of amounts due from Prescription Drug Plans ("PDPs") under Medicare Part D, institutional healthcare providers, the respective state Medicaid programs, third party insurance companies, and private payers. The Corporation's ability to collect outstanding receivables is critical to its results of operations and cash flows. To provide for accounts receivable that could become uncollectible in the future, the Corporation establishes an allowance for doubtful accounts to reduce the carrying value of such receivables to the extent it is probable that a portion or all of a particular account will not be collected.
	The Corporation has an established a process to determine the adequacy of the allowance for doubtful accounts, which relies on analytical tools, specific identification, and benchmarks to arrive at a reasonable allowance. No single statistic or measurement determines the adequacy of the allowance for doubtful accounts. The Corporation monitors and reviews trends by payer classification along with the composition of the Corporation's aging accounts receivable. This review is focused primarily on trends in private and other payers, PDP's, dual eligible co-payments, historic payment patterns of long-term care institutions, and monitoring respective credit risks. In addition, the Corporation analyzes other factors such as revenue days in accounts receivables, denial trends by payer types, payment patterns by payer types, subsequent cash collections, and current events that may impact payment patterns of the Corporation's long-term care institution customers. Accounts receivable are written off after collection efforts have been completed in accordance with the Corporation's policies.
	The Corporation's accounts receivable and summarized aging categories are as follows (dollars in millions):
			(As Adjusted)
			December 31,				September 30,
			2013				2014
	Institutional healthcare providers		$	160.9			$	164.2
	Medicare Part D			31.1				36.9
	Private payer and other			29.7				31.3
	Insured			20				23.1
	Medicaid			11.9				11.7
	Medicare			2.5				3.9
	Allowance for doubtful accounts			(56.7	)			(57.4	)
			$	199.4			$	213.7
	0 to 60 days			55.5	%			57.3	%
	61 to 120 days			18.8				16.9
	Over 120 days			25.7				25.8
				100	%			100	%
	The following is a summary of activity in the Corporation's allowance for doubtful accounts (dollars in millions):
		Beginning Balance				Charges to Costs and Expenses				Write-offs				Ending Balance
	Allowance for doubtful accounts:
	Year ended December 31, 2013		$	56.4			$	22.7			$	(22.4	)		$	56.7
Nine months ended September 30, 2014		$	56.7			$	16.6			$	(15.9	)		$	57.4
NOTE 1—ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Goodwill and Other Intangibles
Goodwill represents the excess purchase price of an acquired entity over the net amounts assigned to assets acquired and liabilities assumed. The Corporation's policy is to perform a qualitative assessment on goodwill impairment to determine whether it is more likely than not (defined as having a likelihood of more than 50 percent) that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. As a result of the Corporation being notified during June 2013 that it will lose its largest customer effective December 31, 2013, the Corporation performed the first step of the two step analysis for the pharmacy services reporting unit during the quarter ended December 31, 2013 and determined that an impairment of goodwill did not occur as a result of this triggering event. The Corporation's fair value as calculated for the step one analysis was approximately 65% greater than current book value.
There have been no impairment triggering events during 2014.
The Corporation's finite-lived intangible assets are comprised primarily of trade names, customer relationship assets, limited distributor relationships, doctors and insurer relationships and non-compete agreements. Finite-lived intangible assets are amortized on a straight-line basis over the course of their lives ranging from 5 to 20 years. For impairment reviews, intangible assets are reviewed on a specific pharmacy basis or as a group of pharmacies depending on the intangible assets under review. The Corporation's goodwill and intangible assets are further described in Note 3.
Restructuring and Impairment Charges
Restructuring and impairment charges in the condensed consolidated financial statements represent amounts expensed for purposes of realigning corporate and pharmacy locations.
Income Taxes
Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Corporation accrues for tax obligations as required by facts and circumstances in the various regulatory environments. Deferred tax assets and liabilities are more fully described in Note 9.
Mandatorily Redeemable Interest
The Corporation acquired 37.5% of the membership interests of OncoMed Specialty, LLC ("Onco") while also obtaining control of the business. As further discussed in Note 2, the subsidiary is consolidated in the Corporation's condensed consolidated financial statements and the mandatorily redeemable interest is classified as debt within other long-term liabilities in the condensed consolidated balance sheets.
Measurement Period Adjustments
For the nine months ended September 30, 2014, the Corporation has adjusted certain amounts on the condensed consolidated balance sheet as of December 31, 2013 as a result of measurement period adjustments related to the 2013 acquisitions (See Note 2).
Recently Issued Accounting Pronouncements
On May 28, 2014, the FASB issued Accounting Standard Update ("ASU") No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Corporation on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Corporation is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Corporation has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.
On August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40); Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, which requires management of the Corporation to evaluate whether there is substantial doubt about the Company's ability to continue as a going concern. ASU 2014-15 is effective for the Company in our first quarter of fiscal 2017, with early adoption permitted. The Corporation does not expect this standard to have an impact on the condensed consolidated financial statements upon adoption.
NOTE 2—ACQUISITIONS

ACQUISITIONS

ACQUISITIONS	9 Months Ended
	Sep. 30, 2014
ACQUISITIONS [Abstract]	'
ACQUISITIONS	'
	2014 Acquisitions
	During the nine months ended September 30, 2014, the Corporation completed acquisitions of four long-term care businesses and one infusion business (collectively the "2014 Acquisitions"), none of which were individually significant to the Corporation. The 2014 Acquisitions required cash payments of approximately $114.1 million. The resulting amount of goodwill and identifiable intangibles related to these transactions in the aggregate were $39.5 million and $61.4 million, respectively. The Corporation believes the resulting amount of goodwill reflects its expectation of synergistic benefits of the acquisitions.  Tax deductible goodwill associated with the 2014 Acquisitions was $29.4 million as of September 30, 2014.  The net assets and operating results of the 2014 Acquisitions have been included in the Company's consolidated financial statements from their respective dates of acquisition.
	Amounts contingently payable related to the 2014 Acquisitions, representing payments originating from an earn-out provision of the infusion acquisition, were $1.1 million as of September 30, 2014.
	The amounts recognized as of the acquisition dates for the 2014 Acquisitions, on a combined basis, for assets acquired and liabilities assumed are as follows:
			Amounts Recognized as of Acquisition Date (1)			Measurement Period Adjustments			Amounts Recognized as of Acquisition Date (As Adjusted)
	Accounts receivable		$	25.2		$	-		$	25.2
	Inventory			6.7			0.2			6.9
	Deferred tax assets - current			3			-			3
	Other current assets			3.1			-			3.1
	Equipment and leasehold improvements			4.2			-			4.2
	Other long-term assets			-			-			-
	Deferred tax assets - long-term			4.1			-			4.1
	Identifiable intangibles			61.4			-			61.4
	Goodwill			39.7			(0.2	)		39.5
				147.4			-			147.4
	Current liabilities			26.4			-			26.4
	Deferred tax liabilities - long-term			-			-			-
	Other long-term liabilities			6.9			-			6.9
				33.3			-			33.3
	Total purchase price, less cash acquired		$	114.1		$	-		$	114.1
	-1	Per the purchase price allocations on a combined basis
	The acquisitions on a combined basis had a $10.5 million impact on the consolidated revenues and $0.5 million impact on consolidated net income for the nine months ended September 30, 2014.
	Pro Forma
	The following unaudited pro forma condensed consolidated financial information is not intended to represent or be indicative of the condensed consolidated results of operations or financial condition of the Corporation that would have been reported had the acquisitions been completed as of the date or for the periods presented, and should not be taken as representative of the future consolidated results of operations or financial condition of the Corporation.
	NOTE 2—ACQUISITIONS (Continued)
	The unaudited pro forma results, which includes the historical results of the Corporation as well as the effect of the acquisitions assuming the acquisitions occurred on January 1, 2013. The results may not be indicative of future results and do not include any synergistic benefits which the Corporation may realize. Assuming an effective tax rate exclusive of discrete items for the three and nine months ended September 30, 2013 and 2014, the pro forma results would be as follows (dollars in millions, except per share amounts):
			Three Months Ended September 30,						Nine Months Ended September 30,
			2013			2014			2013		2014
	Revenues		$	494.9		$	513		$	1,484.10	$	1,521.90
	Net income		$	(7.1	)	$	5.7		$	12.9	$	(2.0	)
	Earnings per common share:
	Basic		$	(0.24	)	$	0.19		$	0.44	$	(0.06	)
	Diluted		$	(0.24	)	$	0.19		$	0.43	$	(0.06	)
	2013 Acquisitions
	During the year ended December 31, 2013, the Corporation completed five acquisitions of long-term care businesses (the "2013 Acquisitions"), none of which were, individually or in the aggregate significant to the Corporation. The 2013 Acquisitions of businesses required cash payments of approximately $25.8 million, of which $10.7 million was paid in 2014. The resulting amount of goodwill and identifiable intangibles related to these transactions in the aggregate were $8.0 million and $10.3 million, respectively. The net assets and operating results of acquisitions have been included in the Company's consolidated financial statements from their respective dates of acquisition.
	Amounts contingently payable related to the 2013 Acquisitions, representing payments originating from earn-out provisions, were $0.7 million as of December 31, 2013 and September 30, 2014.
	On December 6, 2013, the Corporation through one of its wholly owned subsidiaries, acquired 37.5% of the issued share capital of Onco for $10.8 million, net of cash acquired. The Corporation's primary purpose in acquiring Onco was to continue to expand pharmacy services through the addition of specialty pharmacy services. The purchase price, as determined by an independent valuation of 100% of Onco, was allocated to the net tangible and identifiable intangible assets based upon their fair values on December 6, 2013 which resulted in identifiable intangible assets of $17.3 million and goodwill of $4.6 million. The Corporation believes the resulting amount of goodwill reflects its expectation of the synergistic benefits of the acquisition. Provisions in the acquisition agreement include a mandatorily redeemable interest whereby the Corporation is required to purchase the remaining capital of Onco on the fifth anniversary of the agreement, if not purchased earlier under the provisions of the acquisition agreement. The Corporation is accounting for the mandatorily redeemable interest of $7.5 million as a debt obligation and subsequently measuring that obligation at fair value. Changes in the fair value of the related debt will be recorded as interest expense in our condensed consolidated statements of operations for the respective periods. In addition, net operating profit or loss of Onco subsequent to the acquisition is recognized based upon the Corporation's ownership interest. In addition, Onco's results are consolidated by the Corporation with 62.5 % of the net operating profit or loss subsequent to the acquisition recognized as an adjustment to interest expense on the mandatorily redeemable interest.
	Total measurement period adjustments for the nine months ended September 30, 2014 resulted in a net adjustment to goodwill of $0.6 million and were related to the 2013 Acquisitions and Onco.
	Other
	For the three months ended September 30, 2013 and September 30, 2014, the Corporation incurred $1.0 million and $3.7 million, respectively, and $4.5 million and $10.0 million for the nine months ended September 30, 2013 and September 30, 2014, respectively, of acquisition-related costs, which have been classified as a component of merger, acquisition, integration costs and other charges .

GOODWILL_AND_INTANGIBLES

GOODWILL AND INTANGIBLES	9 Months Ended
	Sep. 30, 2014
GOODWILL AND INTANGIBLES [Abstract]	'
GOODWILL AND INTANGIBLES	'
	NOTE 3—GOODWILL AND INTANGIBLES
	As of December 31, 2013, as adjusted, and September 30, 2014 the carrying amount of goodwill was $282.0 million and $321.5 million, respectively.
	The following table presents the components of the Corporation's intangible assets (dollars in millions):
		(As Adjusted)
		Balance at						Balance at
	Finite Lived Intangible Assets	31-Dec-13			Additions			30-Sep-14
	Customer and other relationships	$	121.2		$	56.4		$	177.6
	Trade name		60.2			2			62.2
	Non-compete agreements		16.9			3			19.9
	Sub Total		198.3			61.4			259.7
	Accumulated amortization		(62.0	)		(13.6	)		(75.6	)
	Net intangible assets	$	136.3		$	47.8		$	184.1
	Amortization expense relating to finite-lived intangible assets was $3.7 million and $4.9 million for the three months ended September 30, 2013 and 2014, respectively. Amortization expense relating to finite-lived intangible assets was $11.7 million and $13.6 million for the nine months ended September 30, 2013 and 2014, respectively.

CREDIT_AGREEMENT

CREDIT AGREEMENT	9 Months Ended
	Sep. 30, 2014
CREDIT AGREEMENT [Abstract]	'
CREDIT AGREEMENT	'
	NOTE 4—CREDIT AGREEMENT
	On September 17, 2014, the Corporation entered into a credit agreement by and among the Corporation, the lenders named therein (the "Lenders"), Bank of America, N.A., as administrative agent, JP Morgan Chase Bank N.A., as syndication agent, and U.S. Bank, National Association, Citibank, N.A., MUFG Union Bank, N.A., BBVA Compass Bank and SunTrust Bank as co-documentation agents (the "Credit Agreement"). The Credit Agreement replaced the $450.0 million five-year credit agreement dated as of May 2, 2011, among the Corporation, Citibank, N.A., as Administrative Agent, and certain lenders (the "Prior Credit Agreement"). The Credit Agreement consists of a $225.0 million term loan facility and a $310.0 million revolving credit facility. The terms and conditions of the Credit Agreement are customary to facilities of this nature.
	As a result of the payoff of the Prior Credit Agreement, the Corporation recorded a loss on debt extinguishment of $4.3 million in the Condensed Consolidated Statement of Operations during the three months ended September 30, 2014. The loss recorded consisted primarily of deferred financing fees associated with the Prior Credit Agreement.
	As of September 30, 2014, $225.0 million was outstanding under the term loan facility and $135.9 million was outstanding under the revolving credit facility. Indebtedness under the Credit Agreement matures on September 17, 2019, at which time the commitments of the Lenders to make revolving loans also expire.
	The table below summarizes the term debt and revolving credit facility of the Corporation (dollars in millions):
		December 31,		September 30,
	Credit Agreement:	2013		2014
	Term Debt - payable to lenders at LIBOR plus applicable margin (1.95% as of September 30, 2014), matures September 17, 2019	$	-	$	225
	Term Debt - payable to lenders at LIBOR plus applicable margin (2.67% as of December 31, 2013), terminated September 17, 2019		231.3
	Revolving Credit Facility payable to lenders, interest at LIBOR plus applicable margin (1.90% as of September 30, 2014), matures September 17, 2019		-		135.9
	Revolving Credit Facility payable to lenders, interest at base rate plus applicable margin (4.75% as of December 31, 2013), terminated September 17, 2019		-		-
	Total debt		231.3		360.9
	Less: Current portion of long-term debt		12.5		2.8
	Total long-term debt	$	218.8	$	358.1
	NOTE 4—CREDIT AGREEMENT (Continued)
	The Corporation's indebtedness has the following maturities for the remaining life of the Credit Agreement (dollars in millions):
	Year Ending December 31,	Term Debt		Revolving Credit Facility		Total Maturities
	2014	$	-	$	-	$	-
	2015		5.6		-		5.6
	2016		11.3		-		11.3
	2017		11.3		-		11.3
	2018		11.3		-		11.3
	2019		185.5		135.9		321.4
		$	225	$	135.9	$	360.9
	The Credit Agreement provides for the issuance of letters of credit which, when issued, reduce availability under the revolving credit facility. The aggregate amount of letters of credit outstanding as of September 30, 2014 was $2.5 million. After giving effect to the letters of credit, total availability under the revolving credit facility was $171.6 million as of September 30, 2014.
	Borrowings under the Credit Agreement bear interest at a floating rate equal to, at the Corporation's option, a base rate plus a margin between 0.50% and 1.25% per annum, or a Eurodollar Rate plus a margin between 1.50% and 2.25% per annum, in each case depending on the leverage ratio of the Corporation as defined by the Credit Agreement. The base rate is the greater of the prime lending rate in effect on such day, the federal funds effective rate plus 0.50%, and the Eurodollar Rate plus 1.00%. The Credit Agreement also provides for letter of credit fees between 1.50% and 2.25% on the letter of credit exposure, depending on the leverage ratio of the Corporation, and 0.125% on the actual daily amount available to be drawn under such letter of credit. The Corporation will also pay fronting fees on the aggregate letter of credit exposure at a rate separately agreed upon between the Corporation and the issuing bank. The Credit Agreement also provides for a commitment fee payable on the unused portion of the revolving credit facility, which shall accrue at a rate per annum ranging from 0.25% to 0.35%, depending on the leverage ratio of the Corporation.
	The Credit Agreement contains customary affirmative and negative covenants, as well as customary events of default. The Credit Agreement also requires the Corporation to satisfy an interest coverage ratio and a leverage ratio. The interest charge coverage ratio as of the last day of any fiscal quarter can be no less than: 3.00:1.00. The Leverage Ratio as of the last day of any fiscal quarter of the Corporation cannot exceed 3.75:1.00, subject to certain exceptions for permitted acquisitions. In addition, capital expenditures (other than those funded with proceeds of asset sales or insurance) are restricted in any fiscal year to 5.0 % of revenues.
	The Corporation was compliant with all debt covenant requirements at September 30, 2014.
	The obligations under the Credit Agreement are guaranteed by certain domestic subsidiaries of the Corporation and secured by liens on substantially all of the Corporation's assets.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2014
COMMITMENTS AND CONTINGENCIES [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE 5—COMMITMENTS AND CONTINGENCIES
	Legal Action and Regulatory
	The Corporation maintains liabilities for certain of its outstanding investigations and litigation. In accordance with the provisions of U.S. GAAP for contingencies, the Corporation accrues for a liability when it is probable that such a liability has been incurred and the amount of the loss can be reasonably estimated. The Corporation is the subject of certain investigations and is a defendant in a number of cases, including those discussed below.
	On April 15, 2013, the U.S. Department of Justice, through the U.S. Attorney's Office for the Eastern District of Virginia, filed a complaint in the United States District Court for the Eastern District of Virginia against the Corporation's two pharmacies in Virginia Beach, Virginia and Fredericksburg, Virginia alleging that these two pharmacies failed to comply with the Controlled Substances Act ("CSA") by dispensing Schedule II drugs without a proper prescription. The parties reached a settlement in December 2013 and filed a stipulation for dismissal of the case in January 2014. Under the settlement, the Corporation paid a $1.0 million fine and will enter into a Memorandum of Agreement ("MOA") with the DEA through which it will agree to certain CSA compliance obligations. The precise terms of the MOA are currently being negotiated between the parties. In connection with the settlement, the Corporation did not admit liability for the alleged CSA violations.
	On June 10, 2013, the United States District Court for the Eastern District of Wisconsin unsealed two consolidated qui tam complaints filed in 2009 and 2011 by relators who are former employees of the Corporation and a company acquired by the Corporation. The United States, acting through the U.S. Attorney's Office in Wisconsin, intervened in part and declined to intervene in part and filed its complaint in intervention on August 9, 2013, when the matter was formally brought to the Corporation's attention. The Government's complaint seeks statutory fines for the Corporation's alleged dispensing of Schedule II controlled substances without a valid prescription in violation of the CSA. It also seeks monetary damages and equitable relief alleging that this conduct caused false claims to be submitted in violation of the Federal False Claims Act (the "FCA"). The Corporation moved to dismiss the government's complaint for failure to state a claim upon which relief may be granted but the Court denied the Corporation's motion on September 3, 2014.  With regard to the portion of the relators' complaint on which the Government did not intervene, on November 15, 2013, the relators dismissed their claims against the Corporation alleging that the Corporation submitted false claims to Medicare Part D and to Medicaid for drugs in connection with which the Corporation allegedly received kickbacks from the manufacturer in the form of market share rebates and other remuneration, all in violation of the Federal Anti Kickback Statute (the "AKS/FCA" claims). The United States stipulated to the dismissal of those and other non-intervened counts, and the Court approved the dismissal without prejudice of those counts on November 20, 2013.  The relators pursued their claim under the retaliatory termination provisions of the FCA. On September 3, 2014, the Court denied the Corporation's motion to dismiss the relators' retaliatory termination claim.  The Corporation intends to vigorously defend itself in both matters.
	On October 29, 2013, a complaint was filed in the United States District Court for the Southern District of Florida by Pines Nursing Homes (77), Inc. as a putative class action against the Corporation. The complaint alleged that the Corporation sent unsolicited advertisements promoting the Corporation's goods or services by facsimile to individuals or entities, and that such communications did not include an opt-out clause, all in violation of the federal Telephone Consumer Protection Act ("TCPA").  The Complaint did not specify the amount of damages sought, but the TCPA provides a statutory remedy of $500 per facsimile communication sent in violation of the statute, which may be trebled in the event of a willful violation.   On August 18, 2014, the Corporation entered into a Settlement Agreement with the putative class and class counsel resolving all claims raised in the complaint.  The parties moved on September 8, 2014 for, among other things, certification of the putative class for the purposes of effectuating the settlement and preliminary approval of the parties' settlement, and have requested a hearing on that motion.  No hearing has yet been set on that motion and the Corporation awaits a decision on the motion for preliminary approval of the settlement.
	On November 12, 2013, a relator, Fox Rx, Inc. ("Fox"), on behalf of the U.S. Government and various state governments and the District of Columbia, filed a complaint in the United States District Court for the Southern District of New York against the Corporation alleging that the Corporation violated the FCA by submitting false claims to Fox, other Medicare Part D sponsors and to Medicaid, by allegedly billing for expired drugs or for brand drugs when generic drugs should have been substituted. Following the U.S. Government's decision to decline to intervene in the case, the complaint was unsealed and served on the Corporation. The Corporation moved to dismiss the complaint on February 28, 2014 and on August 12, 2014, the court granted the Corporation's motion. On September 10, 2014, Fox filed its notice of appeal but subsequently filed a stipulation of dismissal and the appeal was dismissed on September 30, 2014.
	On November 20, 2013 the complaint filed by a relator, Robert Gadbois, on behalf of the U.S. Government and various state governments, was unsealed by the United States District for the District of Rhode Island against the Corporation alleging that the Corporation dispensed controlled and non-controlled substances in violation of the CSA and that, as a result, the dispenses were not eligible for payment and that the claims the Corporation submitted to the Government were false within the meaning of the FCA. The U.S. Government and the various state governments have declined to intervene in this case. The case therefore has been unsealed and the relator served the Second Amended Complaint on the Corporation. On October 3, 2014, the Corporation's motion to dismiss was granted by the court.  The relator has appealed the court's decision.  The Corporation intends to continue to defend the case vigorously.
	NOTE 5—COMMITMENTS AND CONTINGENCIES (Continued)
	On March 4, 2011, a relator, Mark Silver, on behalf of the U.S. Government and various state governments, filed a complaint in the United States District for the District of New Jersey against the Corporation alleging that the Corporation violated the FCA and Federal Anti-Kickback Statute through its agreements to provide prescription drugs to nursing homes under certain Medicare and Medicaid programs. On February 19, 2013, the U.S. Government declined to intervene in the case. The complaint has been amended several times, most recently on November 12, 2013, and thereafter served upon the Corporation. On December 6, 2013, the Corporation moved to dismiss the amended complaint for failure to state a claim upon which relief may be granted and on September 29, 2014, the court denied its motion with regard to the substantive argument, but granted the motion in part by limiting the relevant time period. The Corporation believes the allegations are meritless and intends to vigorously defend itself against these allegations.
	On January 31, 2014, a relator, Frank Kurnik, on behalf of the U.S. Government and various state governments served its complaint filed in the United States District for the District of South Carolina alleging that the Corporation solicited and received remuneration in violation of the Federal Anti-Kickback Statute from drug manufacturer Amgen in exchange for preferring and promoting Amgen's drug Aranesp over a competing drug called Procrit. The U.S. Government and the various states declined to intervene in the case.  On April 7, 2014, the Corporation moved to dismiss the complaint and on July 23, 2014, the motion was denied.  The Corporation believes the allegations are meritless and intends to vigorously defend itself against these allegations.
	The U.S. Department of Justice, through the U.S. Attorney's Office for the Western District of Virginia, is investigating whether the Corporation's activities in connection with the agreements it had with the manufacturer of the pharmaceutical Depakote violated the False Claims Act or the Anti-Kickback Statute. The Corporation is cooperating with this investigation and believes it has complied with all applicable laws and regulations. On May 29, 2014, the United States District Court for the Western District of Virginia entered an order unsealing two previously partially sealed qui tam complaints, entitled United States, et al., ex rel. Spetter v. Abbott Laboratories. Inc., Omnicare, Inc., and PharMerica Corp., No. 1:07-cv-00006 and United States, et al., ex rel. McCoyd v. Abbott Laboratories, Omnicare, Inc., PharMerica Corp., and Miles White, No. 1:07-cv-0008, and the United States' Notice of Intervention in the cases. The complaints allege violations of the False Claims Act from activities in connection with agreements the Corporation had with the manufacturer of the pharmaceutical Depakote that allegedly violated the Anti-Kickback Statute. The Corporation believes the allegations are meritless and intends to vigorously defend itself.
	On September 10, 2014, the Corporation filed a Complaint in Jefferson Circuit Court in Louisville, Kentucky against AmerisourceBergen Drug Corporation ("ABDC") for breach of the Amended Prime Vendor Agreement ("Amended PVA").  The Corporation subsequently filed a First Amended Complaint asserting additional breaches of the Amended PVA and filed a motion seeking a preliminary injunction enjoining ABDC from instituting certain drug substitution programs.  On September 10, 2014, ABDC filed suit in the Court of Chancery of the State of Delaware seeking a declaration that it is not in breach of the Amended PVA.  The amounts disputed by ABDC generally relate to certain rebates owed by ABDC under the Amended PVA, which are approximately $8.5 million for the second quarter of 2014 and $12.3 million for the third quarter of 2014 and are likely to be of an approximately similar magnitude as the third quarter 2014 in future quarters. The Corporation has moved to dismiss the Delaware proceeding for lack of subject matter jurisdiction or, in the alternative, to dismiss or stay the action pending resolution of the Kentucky action.  ABDC has filed a motion to stay the Kentucky action.  The Corporation intends to vigorously pursue its claims in whichever (or both) action proceeds.  The Corporation believes the aggregate amount of its claims currently approximate $20.8 million as of September 30, 2014 which is reflected as a receivable and included in prepaids and other assets in the accompanying unaudited condensed consolidated balance sheets. At this time, the Corporation is unable to determine the ultimate impact of these litigation proceedings on its consolidated financial condition, results of operations, or liquidity.  The litigation proceedings with ABDC could continue for an extended period of time, likely longer than 18 months.  Although the Corporation is confident in the merits of its case, until the resolution or settlement of such proceedings, the Corporation cannot provide any assurances about the collectability of the disputed amounts owed by ABDC.
	On March 6, 2012, a relator, Fox, a former Part D Plan Sponsor, filed a complaint against the Corporation in the United States District Court for the Southern District of Ohio. Fox filed an amended complaint on October 2, 2012. The case was transferred to the United States District Court for the Western District of Virginia on March 27, 2013. Fox alleges that the Corporation engaged in a variety of schemes relating to the dispensing of atypical antipsychotics and the drug Depakote, including allegedly dispensing drugs for unapproved uses, allegedly receiving illegal kickbacks in the form of rebates, and other alleged violations. Fox also alleges that the Corporation improperly inflated dispensing fees by splitting prescriptions into partial fills. Fox alleges that these activities caused the subsequent claims submitted to Medicare and Medicaid to be rendered false within the meaning of the federal FCA and various state analogues. The United States declined to intervene on September 8, 2014 and the case was unsealed on September 10, 2014, at which time the Court ordered Fox to serve the complaint upon the Corporation. Fox has until January 8, 2015 to serve the Corporation with the complaint but has not yet done so. The Corporation intends to vigorously defend itself if and when Fox serves the complaint.
	In addition, the Corporation is involved in certain legal actions and regulatory investigations arising in the ordinary course of business. At September 30, 2014, the Corporation had accrued approximately $40.1 million related to the legal actions and investigations.
	NOTE 5—COMMITMENTS AND CONTINGENCIES (Continued)
	California Medicaid
	On August 14, 2013, the California Department of Health Care Service ("DHCS") announced its intent to implement a ten (10) percent reimbursement reduction for numerous healthcare providers, including long term care pharmacies. Originally, the DHCS received federal approval for the reduction effective June 1, 2011, but the DHCS had been prevented from implementing the reductions due to a court injunction. The United States Court of Appeals for the Ninth Circuit denied the plaintiffs' motion for a stay of mandate, allowing for the implementation of the reimbursement reduction.
	The DHCS implemented the reduction prospectively beginning in the first quarter of 2014, however the reduction did not have a significant impact on the Corporation's results of operations. In addition, the DHCS will begin recouping a percentage of provider payments representing a ten (10) percent reduction on certain drug reimbursements retroactive to June 1, 2011. These retroactive recoveries have not yet been announced by DHCS. The Corporation has previously recorded a $3.3 million liability and reduction of revenue which represents its best estimate of the expected amount of recoveries from June 1, 2011 through December 31, 2013.
	FUL and AMP Changes
	The reimbursement rates for pharmacy services under Medicaid are determined on a state-by-state basis subject to review by CMS and applicable federal law. Although Medicaid programs vary from state to state, they generally provide for the payment of certain pharmacy services, up to the established limits, at rates determined in accordance with each state's regulations. Federal regulations and the regulations of certain states establish "upper limits" for reimbursement of certain prescription drugs under Medicaid (these upper limits being the "FUL").
	The 2010 Health Care Reform Legislation amended the Deficit Reduction Act of 2005 ("DRA") to change the definition of the FUL by requiring the calculation of the FUL as no less than 175 % of the weighted average, based on utilization, of the most recently reported monthly Average Manufacturer's Price ("AMP") for pharmaceutically and therapeutically equivalent multi-source drugs available through retail community pharmacies nationally. In addition, the definition of AMP changed to reflect net sales only to drug wholesalers that distribute to retail community pharmacies and to retail community pharmacies that directly purchase from drug manufacturers. Further, the 2010 Health Care Reform Legislation continues the current statutory exclusion of prompt pay discounts offered to wholesalers and adds three (3) other exclusions to the AMP definition: i) bona fide services fees; ii) reimbursement for unsalable returned goods (recalled, expired, damaged, etc.); and iii) payments from and rebates/discounts to certain entities not conducting business as a wholesaler or retail community pharmacy. In addition to reporting monthly, the manufacturers are required to report the total number of units used to calculate each monthly AMP. Centers for Medicare and Medicaid Services ("CMS") will use this information when it establishes FULs as a result of the new volume-weighted requirements pursuant to the 2010 Health Care Reform Legislation.
	In September 2011, CMS issued the first draft FUL reimbursement files for multiple source drugs, including the draft methodology used to calculate the FULs in accordance with the Health Care Legislation. CMS continues to release monthly data and a three-month rolling average and is expected to do so going forward. CMS has not posted monthly AMPs for individual drugs, but only posted the weighted average of monthly AMPs in a FUL group and the calculation methodology.
	The Office of Information and Regulatory Affairs website provides no date for when the final rule will be released. CMS will continue to post draft monthly FULs. The Corporation will continue to analyze the draft monthly, including the relationship of those FULs to the National Average Drug Acquisition pricing.
	Medicare Part D Changes
	In a May 23, 2014 Final Rule entitled "Medicare Program: Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs," CMS finalized a requirement that effective June 1, 2015, all prescribers of Part D covered drugs must be enrolled as Medicare providers (or be granted a valid opt-out affidavit on file with a Part A or Part B Medicare Administrative Contractor) in order for a claim to be covered under Medicare Part D. CMS also finalized several specific requirements to reduce prescriber fraud, waste, and abuse. The Corporation is unable to evaluate the full impact of these changes on its business at this time.
	NOTE 5—COMMITMENTS AND CONTINGENCIES (Continued)
	Acquisitions
	The Corporation has historically acquired the stock or assets of businesses with prior operating histories. Acquired companies may have unknown or contingent liabilities, including liabilities for failure to comply with healthcare laws and regulations, medical and general professional liabilities, workers' compensation liabilities, previous tax liabilities, and unacceptable business practices. Although the Corporation institutes policies designed to conform practices to its standards following completion of acquisitions, there can be no assurance that the Corporation will not become liable for past activities that may later be asserted to be improper by private plaintiffs or government agencies. While the Corporation generally seeks to obtain indemnification from prospective sellers covering such matters, there can be no assurance that any such matter will be covered by indemnification, or if covered, that such indemnification will be adequate to cover potential losses and fines. In the ordinary course of business, the Corporation enters into contracts containing standard indemnification provisions and indemnifications specific to a transaction such as business acquisitions and disposals of an operating facility. These indemnifications may cover claims against employment-related matters, governmental regulations, environmental issues, tax matters, as well as customer, third party payer, supplier, and contractual relationships. Obligations under these indemnities generally would be initiated by a breach of the terms of the contract or by a third party claim or event.
	Prime Vendor Agreement
	On January 25, 2013 the Corporation renegotiated its Amended PVA with ABDC effective January 1, 2013. The Amended PVA modified the previous agreement, which was set to expire September 30, 2013 and extended its term until September 30, 2016.
	The Amended PVA requires the Corporation to purchase certain levels of brand and non-injectable generic drugs from ABDC. The Amended PVA does provide the flexibility for the Corporation to contract with other suppliers. If the Corporation fails to adhere to the contractual purchase provisions, ABDC has the ability to increase the Corporation's drug pricing under the terms of the Amended PVA.
	The Corporation and ABDC are parties to certain legal proceedings with respect to the Amended PVA as further described above.
	Employment Agreements
	The Corporation has entered into employment agreements with certain of its executive officers. During the employment period, certain executive officers will be eligible to (i) participate in any short-term and long-term incentive programs established or maintained by the Corporation, (ii) participate in all incentive, savings and retirement plans and programs of the Corporation, (iii) participate, along with their dependents, in all welfare benefit plans and programs provided by the Corporation, and (iv) receive four weeks of paid vacation per calendar year.
	The type of compensation due to each of the executive officers in the event of the termination of their employment period varies depending on the nature of the termination. The employment agreements generally do not entitle the executive officers to any additional payment or benefits solely upon the occurrence of a change in control but do provide additional payments or benefits or both upon a termination of employment in connection with a change in control. Additionally, the vesting of certain equity based grants made to certain executive officers accelerate upon the occurrence of a change in control.

MERGER_ACQUISITION_INTEGRATION

MERGER, ACQUISITION, INTEGRATION COSTS AND OTHER CHARGES	9 Months Ended
	Sep. 30, 2014
MERGER, ACQUISITION, INTEGRATION COSTS AND OTHER CHARGES [Abstract]	'
MERGER, ACQUISITION, INTEGRATION COST AND OTHER CHARGES	'
	NOTE 6—MERGER, ACQUISITION, INTEGRATION COSTS AND OTHER CHARGES
	Merger, acquisition, integration costs and other charges combined were $1.1 million and $3.8 million for the three months ended September 30, 2013 and 2014, respectively, and $6.6 million and $10.3 million for the nine months ended September 30, 2013 and 2014, respectively.
	The merger, integration costs and other charges component for the three months ended September 30, 2013 and 2014 were $0.1 million and $0.1 million, respectively, and $2.1 million and $0.3 million for the nine months ended September 30, 2013 and 2014, respectively. These costs primarily represent employee related and facility costs associated with consolidating past acquisitions.  The acquisition related costs component for the three months ended September 30, 2013 and 2014 were $1.0 million and $3.7 million, respectively, and $4.5 million and $10.0 million for the nine months ended September 30, 2013 and 2014, respectively. These costs primarily represent severance and other payments associated with former employees, professional fees, lease costs and other duplicative costs associated with current and future acquisitions.
	NOTE 7—RESTRUCTURING COSTS AND OTHER CHARGES

RESTRUCTURING_COSTS_AND_OTHER_

RESTRUCTURING COSTS AND OTHER CHARGES	9 Months Ended
	Sep. 30, 2014
RESTRUCTURING COSTS AND OTHER CHARGES [Abstract]	'
RESTRUCTURING COSTS AND OTHER CHARGES	'
	In July 2013, the Corporation commenced the implementation of its restructuring plan as a result of the loss of two of the Corporation's significant customers, Kindred Healthcare ("Kindred") and Golden Living. The plan is a major initiative primarily designed to optimize operational efficiency while ensuring that the Corporation remains well-positioned to serve its clients and achieve sustainable, long-term growth.  The Corporation's restructuring plan includes steps to rightsize its cost structure by adjusting its workforce and facility plans to reflect anticipated business needs.
	The Corporation recorded restructuring costs and other related charges of approximately of $1.0 million and $0.1 million during the three months ended September 30, 2013 and 2014, respectively, and $1.0 million and $3.2 million during the nine months ended September 30, 2013 and 2014, respectively. The restructuring charges primarily included severance pay, the buy-out of employment agreements, lease terminations, and other exit-related asset disposals, professional fees and facility exit costs.
	The following table presents the components of the Corporation's restructuring liability (dollars in millions):
		Balance at							Balance at
		31-Dec-13		Accrual		Utilized Amounts			30-Sep-14
	Employee Severance and related costs	$	1.8	$	2.1	$	(3.5	)	$	0.4
	Facility costs		0.8		1.1		(0.7	)		1.2
		$	2.6	$	3.2	$	(4.2	)	$	1.6
	The liability at September 30, 2014 represent amounts not yet paid relating to actions taken in connection with the program (primarily lease payments and severance costs).

COMMON_STOCK_PREFERRED_STOCK_T

COMMON STOCK, PREFERRED STOCK, TREASURY STOCK, STOCK-BASED COMPENSATION AND OTHER BENEFITS	9 Months Ended
	Sep. 30, 2014
COMMON STOCK, PREFERRED STOCK, TREASURY STOCK, STOCK-BASED COMPENSATION AND OTHER BENEFITS [Abstract]	'
COMMON STOCK, PREFERRED STOCK, TREASURY STOCK, STOCK-BASED COMPENSATION AND OTHER BENEFITS	'
	NOTE 8—COMMON STOCK, PREFERRED STOCK, TREASURY STOCK, STOCK-BASED COMPENSATION AND OTHER BENEFITS
	Treasury Stock Purchases
	In August 2010, the Board of Directors authorized a share repurchase of up to $25.0 million of the Corporation's common stock, of which $10.5 million was used. On July 2, 2012 the Board of Directors authorized an increase to the remaining portion of the existing share repurchase program that allows the Corporation to again repurchase up to a maximum of $25.0 million of the Corporation's common stock. Approximately $19.7 million remained available under the program as of September 30, 2014. Share repurchases under this authorization may be made in the open market through unsolicited or solicited privately negotiated transactions, or in such other appropriate manner, and are funded from available cash. The amount and timing of the repurchases, if any, would be determined by the Corporation's management and would depend on a variety of factors including price, corporate and regulatory  requirements, capital availability and other market conditions. Common stock acquired through the share repurchase program would be held as treasury shares and may be used for general corporate purposes, including reissuance in connection with acquisitions, employee stock option exercises or other employee stock plans. The share repurchase program does not have an expiration date and may be limited, terminated or extended at any time without prior notice. During the nine months ended September 30, 2014, the Corporation did not repurchase shares of common stock under the share repurchase program.
	The Corporation may redeem shares from employees upon the vesting of the Corporation's stock awards for minimum statutory tax withholding purposes. The Corporation redeemed 200,334 shares of certain vested awards for an aggregate price of approximately $5.1 million during the nine months ended September 30, 2014. These shares have also been designated by the Corporation as treasury stock.
	As of September 30, 2014, the Corporation had a total of 2,617,305 shares held as treasury stock.
	NOTE 8—COMMON STOCK, PREFERRED STOCK, TREASURY STOCK, STOCK-BASED COMPENSATION AND OTHER BENEFITS (Continued)
	Stock Option Activity
	Stock options were not granted to officers and employees during 2013 or the nine months ended September 30, 2014. The following table summarizes option activity for the periods presented:
		Number of Shares		Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Term		Aggregate Intrinsic Value (in millions)
	Outstanding shares at December 31, 2013	1,289,573		$	14.63	2.9 years		$	8.9
	Exercised	-278,350			14.77
	Canceled	-87,799			12.67
	Expired	-859			14.41
	Outstanding shares at September 30, 2014	922,565		$	14.63	2.3 years		$	9
	Exercisable shares at September 30, 2014	827,016		$	15.06	2.2 years		$	7.7
	Nonvested Shares
	The following table summarizes nonvested share activity for the periods presented:
			Number of Shares			Weighted- Average Grant Date Fair Value
	Outstanding shares at December 31, 2013			1,096,674		$	13.47
	Granted - Restricted Stock Units			196,126			25.58
	Granted - Performance Share Units			247,290			20.01
	Forfeited			(102,591	)		15.67
	Vested			(487,713	)		12.37
	Outstanding shares at September 30, 2014			949,786		$	18
	The weighted average remaining term and intrinsic value of non-vested shares as of September 30, 2014 was 2.6 years and $23.2 million, respectively.

INCOME_TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2014
INCOME TAXES [Abstract]	'
INCOME TAXES	'
	NOTE 9—INCOME TAXES
	The provision for income taxes is based upon the Corporation's estimate of annual taxable income or loss for each respective accounting period. The following table summarizes our provision for income taxes for the periods presented (dollars in millions):
		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2014			2013			2014
	Provision (benefit) for income taxes	$	4.2		$	2.2		$	19.3		$	2.9
	Total provision as a percentage of pre-tax income (loss)		NM	*		21	%		57.1	%		45.3	%
	*NM - Not Meaningful
	The provision for income taxes for the nine months ended September 30, 2013 and 2014 was significantly impacted by the Corporation's $17.4 million and $28.9 million of settlement, litigation and other related charges, respectively. The Corporation has concluded that the charges in each period will be partially non-tax deductible and has accounted for the absence of a tax benefit as a discrete item in the tax provision calculation. The partial non-deductibility of the charges resulted in an increase in the tax provision for the nine months ended September 30, 2013 and 2014 of approximately $6.6 million and $2.0 million, respectively.  Also included in the discrete items for the three and nine month periods ended September 30, 2013 and 2014 is the impact of the true up of the provision to the respective tax returns.  Excluding the impact of the discrete tax items, the provision for income taxes as a percentage of pre-tax income before the charges would have been 38.1 % and 37.0% for the nine months ended September 30, 2013 and 2014, respectively. The decrease in the rate from the prior year, after excluding the impact of the discrete items, was a result of net deductible permanent differences for the nine months ended September 30, 2014.
	NOTE 9—INCOME TAXES (Continued)
	The Corporation derives a current federal and state income tax benefit from the impact of deductions associated with the amortization of tax deductible goodwill acquired through business combinations. The tax basis of the Corporation's tax deductible goodwill was approximately $128.5 million and $149.1 million at December 31, 2013 (as adjusted) and September 30, 2014, respectively. The future tax benefits of the tax-deductible goodwill are included in the Corporation's deferred tax assets.
	The Corporation recognizes an asset or liability for the deferred tax consequences of temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements. These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets are recovered or liabilities are settled. The Corporation also recognizes as deferred tax assets the future tax benefits from net operating loss carryforwards. As of September 30, 2014, the Corporation has $5.2 million ($1.8 million tax benefit) of federal net operating loss carryforwards recorded related to a 2013 acquisition and $24.8 million ($8.7 million deferred tax benefit) related to a 2014 acquisition. The Corporation's ability to utilize these loss carryovers is limited, but the Corporation expects that it will be able to use the recorded amount which takes into account the limitations of the carryforwards and has not recorded any valuation allowance for the associated deferred tax asset. The Corporation has state net operating loss carryforwards representing a tax benefit of $7.2 million and valuation allowances totaling $4.1 million. The net operating losses have carryforward periods ranging from 1 to 20 years depending on the taxing jurisdiction.
	A valuation allowance is provided for the Corporation's deferred tax assets if it is more likely than not that some portion or all of the net deferred tax assets will not be realized. The Corporation recognized deferred tax assets totaling $18.2 million at December 31, 2013 and $28.6 million at September 30, 2014, net of state valuation allowances of $4.1 million.
	As of December 31, 2013 and September 30, 2014, the Corporation had no reserves recorded for unrecognized tax benefits for U.S. federal and state tax jurisdictions.
	The federal statute of limitations remains open for tax years 2011 through 2013.
	State tax jurisdictions generally have statutes of limitation ranging from three to five years. The Corporation is generally no longer subject to state and local income tax examinations by tax authorities for years before 2008. The state income tax impact of federal income tax changes remains subject to examination by various states for a period of up to one year after formal notification of IRS settlement to the states.

EARNINGS_PER_SHARE

EARNINGS PER SHARE	9 Months Ended
	Sep. 30, 2014
EARNINGS PER SHARE [Abstract]	'
EARNINGS PER SHARE	'
	NOTE 10—EARNINGS (LOSS) PER SHARE
	The following table sets forth the computation of basic and diluted earnings (loss) per share (dollars in millions, except per share amounts):
		Three Months Ended September 30,					Nine Months Ended September 30,
		2013			2014		2013		2014
	Numerator:
	Numerator for basic and earnings (loss) per diluted share - net income (loss)	$	-6.2		$	8.5	$	14.5	$	3.6
	Denominator:
	Denominator for basic earnings (loss) per share - weighted average shares		29,655,201			30,073,133		29,645,380		29,944,875
	Effective of dilutive securities (stock options, restricted stock units and performance share units)		-			522,169		304,999		558,053
	Denominator for earnings (loss) per diluted share - adjusted weighted average shares		29,655,201			30,595,302		29,950,379		30,502,928
	Basic earnings (loss) per share	$	-0.21	(b)	$	0.28	$	0.49	$	0.12
	Earnings (loss) per diluted share	$	-0.21	(b)	$	0.28	$	0.48	$	0.12
	Unexercised employee stock options and unvested restricted shares excluded from the effect of dilutive securities above (a)(b)		1,917,486			465,377		2,028,557		481,844
	(a)            These unexercised employee stock options, unvested restricted shares and performance shares that have not yet met performance conditions are not included in the computation of diluted earnings (loss) per share because to do so would be anti-dilutive for the periods presented.
	Stock options and restricted shares and units granted by the Corporation are treated as potential common shares outstanding in computing earnings per diluted share. Performance share units are treated as potential common shares outstanding in computing earnings per diluted share only when the performance conditions are met.
	Common shares repurchased by the Corporation reduce the number of basic shares used in the denominator for basic and diluted earnings (loss) per share.
	(b)            The diluted loss per share for the three months ended September 30, 2013 does not include the effects of potential common shares because its inclusion would be anti-dilutive due to the net loss for the period.
	Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

ORGANIZATION_AND_SUMMARY_OF_SI1

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2014
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Nature of Business	'
	Nature of Business
	PharMerica Corporation (together with its subsidiaries, the "Corporation") is a pharmacy services company that services healthcare facilities, provides pharmacy management services to hospitals, provides specialty infusion services to patients outside a hospital setting, and offers the only national oncology pharmacy in the United States. The Corporation is the second largest institutional pharmacy services company in the United States based on revenues and customer licensed beds under contract, operating 104 institutional pharmacies, 14 specialty infusion pharmacies, and 5 specialty oncology pharmacies in 45 states. The Corporation's customers are typically institutional healthcare providers, such as skilled nursing facilities, nursing centers, assisted living facilities, hospitals, individuals receiving in-home care and other long-term alternative care providers. The Corporation is generally the primary source of supply of pharmaceuticals to its customers. The Corporation also provides pharmacy management services to 89 hospitals in the United States.
Operating Segments	'
	Operating Segments
	The Corporation consists of three operating segments: institutional pharmacy, specialty infusion services and specialty oncology pharmacy. Management believes the nature of the products and services are similar, the payers for the products and services are common among the segments and all segments operate in the healthcare regulatory environment. In addition, the segments are economically similar. Accordingly, management has aggregated the three operating segments into one reporting segment.
Principles of Consolidation	'
	Principles of Consolidation
	All intercompany transactions have been eliminated.
Basis of Presentation	'
	Basis of Presentation
	The accompanying condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X and do not include all of the information and disclosures required by generally accepted accounting principles in the United States ("U.S. GAAP") for complete financial statements. Accordingly, the accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements of the Corporation and related footnotes for the year ended December 31, 2013, included in the Corporation's Annual Report on Form 10-K. The balance sheet as of December 31, 2013 has been derived from the audited consolidated financial statements adjusted for acquisition related measurement period adjustments.
	The results of operations for the interim periods are not necessarily indicative of results of operations for a full year. It is the opinion of management that all necessary adjustments for a fair presentation of the condensed consolidated financial statements for the interim periods have been made and are of a normal recurring nature.
Use of Estimates	'
	Use of Estimates
	The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP which requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates are involved in collectability of accounts receivable, revenue recognition, inventory valuation, supplier rebates, the valuation of long-lived assets and goodwill, and accounting for income taxes. Actual amounts may differ from these estimates.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based upon assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Corporation follows a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	Level 1:	Observable inputs such as quoted prices in active markets;
	Level 2:	Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and
	Level 3:	Unobservable inputs for which there is little or no market data, which require the Corporation to develop its own assumptions.
	NOTE 1—ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
	Assets and liabilities measured at fair value are based on one or more of the following three valuation techniques:
		A.	Market approach: Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.
		B.	Cost approach: Amount that would be required to replace the service capacity of an asset (replacement cost).
		C.	Income approach: Techniques to convert future amounts to a single present amount based upon market expectations (including present value techniques, option-pricing and excess earnings models).
	The financial liabilities recorded at fair value at December 31, 2013 and September 30, 2014 are set forth in the tables below (dollars in millions):
	As of December 31, 2013	Asset/(Liability)				Level 1				Level 2				Level 3				Valuation
																		Technique
	Financial Liabilities
	Deferred Compensation Plan		$	(6.9	)		$	-			$	(6.9	)		$	-			A
	Contingent Consideration			(0.7	)			-				-				(0.7	)		C
	Mandatorily Redeemable Interest			(8.2	)			-				-				(8.2	)		C
	As of September 30, 2014	Asset/(Liability)				Level 1				Level 2				Level 3				Valuation
																		Technique
	Financial Liabilities
	Deferred Compensation Plan		$	(7.7	)		$	-			$	(7.7	)		$	-			A
	Contingent Consideration			(1.8	)			-				-				(1.8	)		C
	Mandatorily Redeemable Interest			(7.5	)			-				-				(7.5	)		C
	The deferred compensation plan liability represents an unfunded obligation associated with the deferred compensation plan offered to eligible employees and members of the Board of Directors of the Corporation. The fair value of the liability associated with the deferred compensation plan is derived using pricing and other relevant information for investments in phantom shares of certain available investment options, primarily mutual funds. This liability is classified as other long-term liabilities in the accompanying condensed consolidated balance sheet.
	The contingent consideration represents future earn-outs associated with the Corporation's acquisition of an institutional pharmacy business purchased in 2013 and an infusion business purchased in 2014. The fair values of the liabilities associated with the contingent consideration were derived using the income approach with unobservable inputs, which included future gross profit forecasts and present value assumptions, and there was little or no market data. The Corporation assessed the fair values of the liabilities as of the acquisition date and will assess quarterly thereafter until settlement. This liability is classified as other long-term liabilities in the accompanying condensed consolidated balance sheet.
	The mandatorily redeemable interest represents a future obligation associated with the Corporation's acquisition of a specialty pharmacy business purchased on December 6, 2013. The mandatorily redeemable interest is classified as a long-term liability and was measured at fair value as of December 31, 2013 and September 30, 2014. The fair value was derived using the income approach with unobservable inputs, which included a future gross profit forecast and present value assumptions, and there was little or no market data.
	There were no transfers between the three-tier fair value hierarchy levels during the periods presented.
	The carrying amounts reported in the accompanying condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, and accounts payable approximate fair value because of the short-term maturity of these instruments. The Corporation's debt approximates fair value due to the terms of the interest being set at variable market interest rates (Level 2).
	NOTE 1—ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Accounts Receivable and Allowance for Doubtful Accounts	'
	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable primarily consist of amounts due from Prescription Drug Plans ("PDPs") under Medicare Part D, institutional healthcare providers, the respective state Medicaid programs, third party insurance companies, and private payers. The Corporation's ability to collect outstanding receivables is critical to its results of operations and cash flows. To provide for accounts receivable that could become uncollectible in the future, the Corporation establishes an allowance for doubtful accounts to reduce the carrying value of such receivables to the extent it is probable that a portion or all of a particular account will not be collected.
	The Corporation has an established a process to determine the adequacy of the allowance for doubtful accounts, which relies on analytical tools, specific identification, and benchmarks to arrive at a reasonable allowance. No single statistic or measurement determines the adequacy of the allowance for doubtful accounts. The Corporation monitors and reviews trends by payer classification along with the composition of the Corporation's aging accounts receivable. This review is focused primarily on trends in private and other payers, PDP's, dual eligible co-payments, historic payment patterns of long-term care institutions, and monitoring respective credit risks. In addition, the Corporation analyzes other factors such as revenue days in accounts receivables, denial trends by payer types, payment patterns by payer types, subsequent cash collections, and current events that may impact payment patterns of the Corporation's long-term care institution customers. Accounts receivable are written off after collection efforts have been completed in accordance with the Corporation's policies.
	The Corporation's accounts receivable and summarized aging categories are as follows (dollars in millions):
			(As Adjusted)
			December 31,				September 30,
			2013				2014
	Institutional healthcare providers		$	160.9			$	164.2
	Medicare Part D			31.1				36.9
	Private payer and other			29.7				31.3
	Insured			20				23.1
	Medicaid			11.9				11.7
	Medicare			2.5				3.9
	Allowance for doubtful accounts			(56.7	)			(57.4	)
			$	199.4			$	213.7
	0 to 60 days			55.5	%			57.3	%
	61 to 120 days			18.8				16.9
	Over 120 days			25.7				25.8
				100	%			100	%
	The following is a summary of activity in the Corporation's allowance for doubtful accounts (dollars in millions):
		Beginning Balance				Charges to Costs and Expenses				Write-offs				Ending Balance
	Allowance for doubtful accounts:
	Year ended December 31, 2013		$	56.4			$	22.7			$	(22.4	)		$	56.7
	Nine months ended September 30, 2014		$	56.7			$	16.6			$	(15.9	)		$	57.4
	NOTE 1—ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Goodwill and Other Intangibles	'
	Goodwill and Other Intangibles
	Goodwill represents the excess purchase price of an acquired entity over the net amounts assigned to assets acquired and liabilities assumed. The Corporation's policy is to perform a qualitative assessment on goodwill impairment to determine whether it is more likely than not (defined as having a likelihood of more than 50 percent) that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. As a result of the Corporation being notified during June 2013 that it will lose its largest customer effective December 31, 2013, the Corporation performed the first step of the two step analysis for the pharmacy services reporting unit during the quarter ended December 31, 2013 and determined that an impairment of goodwill did not occur as a result of this triggering event. The Corporation's fair value as calculated for the step one analysis was approximately 65% greater than current book value.
	There have been no impairment triggering events during 2014.
	The Corporation's finite-lived intangible assets are comprised primarily of trade names, customer relationship assets, limited distributor relationships, doctors and insurer relationships and non-compete agreements. Finite-lived intangible assets are amortized on a straight-line basis over the course of their lives ranging from 5 to 20 years. For impairment reviews, intangible assets are reviewed on a specific pharmacy basis or as a group of pharmacies depending on the intangible assets under review. The Corporation's goodwill and intangible assets are further described in Note 3.
Restructuring and Impairment Charges	'
	Restructuring and Impairment Charges
	Restructuring and impairment charges in the condensed consolidated financial statements represent amounts expensed for purposes of realigning corporate and pharmacy locations.
Income Taxes	'
	Income Taxes
	Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Corporation accrues for tax obligations as required by facts and circumstances in the various regulatory environments. Deferred tax assets and liabilities are more fully described in Note 9.
Mandatorily Redeemable Interest	'
	Mandatorily Redeemable Interest
	The Corporation acquired 37.5% of the membership interests of OncoMed Specialty, LLC ("Onco") while also obtaining control of the business. As further discussed in Note 2, the subsidiary is consolidated in the Corporation's condensed consolidated financial statements and the mandatorily redeemable interest is classified as debt within other long-term liabilities in the condensed consolidated balance sheets.
Measurement Period Adjustments	'
	Measurement Period Adjustments
	For the nine months ended September 30, 2014, the Corporation has adjusted certain amounts on the condensed consolidated balance sheet as of December 31, 2013 as a result of measurement period adjustments related to the 2013 acquisitions (See Note 2).
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recently Issued Accounting Pronouncements
	On May 28, 2014, the FASB issued Accounting Standard Update ("ASU") No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Corporation on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Corporation is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Corporation has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.
	On August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40); Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, which requires management of the Corporation to evaluate whether there is substantial doubt about the Company's ability to continue as a going concern. ASU 2014-15 is effective for the Company in our first quarter of fiscal 2017, with early adoption permitted. The Corporation does not expect this standard to have an impact on the condensed consolidated financial statements upon adoption.
	NOTE 2—ACQUISITIONS

ORGANIZATION_AND_SUMMARY_OF_SI2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2014
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Financial Liability and Non-Financial Assets Recorded at Fair Value	'
	The financial liabilities recorded at fair value at December 31, 2013 and September 30, 2014 are set forth in the tables below (dollars in millions):
	As of December 31, 2013	Asset/(Liability)				Level 1				Level 2				Level 3				Valuation
																		Technique
	Financial Liabilities
	Deferred Compensation Plan		$	(6.9	)		$	-			$	(6.9	)		$	-			A
	Contingent Consideration			(0.7	)			-				-				(0.7	)		C
	Mandatorily Redeemable Interest			(8.2	)			-				-				(8.2	)		C
	As of September 30, 2014	Asset/(Liability)				Level 1				Level 2				Level 3				Valuation
																		Technique
	Financial Liabilities
	Deferred Compensation Plan		$	(7.7	)		$	-			$	(7.7	)		$	-			A
	Contingent Consideration			(1.8	)			-				-				(1.8	)		C
	Mandatorily Redeemable Interest			(7.5	)			-				-				(7.5	)		C
Accounts Receivable and Summarized Aging Categories	'
	The Corporation's accounts receivable and summarized aging categories are as follows (dollars in millions):
			(As Adjusted)
			December 31,				September 30,
			2013				2014
	Institutional healthcare providers		$	160.9			$	164.2
	Medicare Part D			31.1				36.9
	Private payer and other			29.7				31.3
	Insured			20				23.1
	Medicaid			11.9				11.7
	Medicare			2.5				3.9
	Allowance for doubtful accounts			(56.7	)			(57.4	)
			$	199.4			$	213.7
	0 to 60 days			55.5	%			57.3	%
	61 to 120 days			18.8				16.9
	Over 120 days			25.7				25.8
				100	%			100	%
Allowance for Doubtful Accounts	'
	The following is a summary of activity in the Corporation's allowance for doubtful accounts (dollars in millions):
		Beginning Balance				Charges to Costs and Expenses				Write-offs				Ending Balance
	Allowance for doubtful accounts:
	Year ended December 31, 2013		$	56.4			$	22.7			$	(22.4	)		$	56.7
	Nine months ended September 30, 2014		$	56.7			$	16.6			$	(15.9	)		$	57.4
	NOTE 1—ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

ACQUISITIONS_Tables

ACQUISITIONS (Tables)	9 Months Ended
	Sep. 30, 2014
ACQUISITIONS [Abstract]	'
Schedule of Purchase Price Allocation	'
	The amounts recognized as of the acquisition dates for the 2014 Acquisitions, on a combined basis, for assets acquired and liabilities assumed are as follows:
			Amounts Recognized as of Acquisition Date (1)			Measurement Period Adjustments			Amounts Recognized as of Acquisition Date (As Adjusted)
	Accounts receivable		$	25.2		$	-		$	25.2
	Inventory			6.7			0.2			6.9
	Deferred tax assets - current			3			-			3
	Other current assets			3.1			-			3.1
	Equipment and leasehold improvements			4.2			-			4.2
	Other long-term assets			-			-			-
	Deferred tax assets - long-term			4.1			-			4.1
	Identifiable intangibles			61.4			-			61.4
	Goodwill			39.7			(0.2	)		39.5
				147.4			-			147.4
	Current liabilities			26.4			-			26.4
	Deferred tax liabilities - long-term			-			-			-
	Other long-term liabilities			6.9			-			6.9
				33.3			-			33.3
	Total purchase price, less cash acquired		$	114.1		$	-		$	114.1
	-1	Per the purchase price allocations on a combined basis
Schedule of Pro Forma Financial Information	'
	The unaudited pro forma results, which includes the historical results of the Corporation as well as the effect of the acquisitions assuming the acquisitions occurred on January 1, 2013. The results may not be indicative of future results and do not include any synergistic benefits which the Corporation may realize. Assuming an effective tax rate exclusive of discrete items for the three and nine months ended September 30, 2013 and 2014, the pro forma results would be as follows (dollars in millions, except per share amounts):
			Three Months Ended September 30,						Nine Months Ended September 30,
			2013			2014			2013		2014
	Revenues		$	494.9		$	513		$	1,484.10	$	1,521.90
	Net income		$	(7.1	)	$	5.7		$	12.9	$	(2.0	)
	Earnings per common share:
	Basic		$	(0.24	)	$	0.19		$	0.44	$	(0.06	)
	Diluted		$	(0.24	)	$	0.19		$	0.43	$	(0.06	)

GOODWILL_AND_INTANGIBLES_Table

GOODWILL AND INTANGIBLES (Tables)	9 Months Ended
	Sep. 30, 2014
GOODWILL AND INTANGIBLES [Abstract]	'
Finite Lived Intangible Assets	'
	The following table presents the components of the Corporation's intangible assets (dollars in millions):
		(As Adjusted)
		Balance at						Balance at
	Finite Lived Intangible Assets	31-Dec-13			Additions			30-Sep-14
	Customer and other relationships	$	121.2		$	56.4		$	177.6
	Trade name		60.2			2			62.2
	Non-compete agreements		16.9			3			19.9
	Sub Total		198.3			61.4			259.7
	Accumulated amortization		(62.0	)		(13.6	)		(75.6	)
	Net intangible assets	$	136.3		$	47.8		$	184.1

CREDIT_AGREEMENT_Tables

CREDIT AGREEMENT (Tables)	9 Months Ended
	Sep. 30, 2014
CREDIT AGREEMENT [Abstract]	'
Term Debt and Revolving Credit Facility	'
	The table below summarizes the term debt and revolving credit facility of the Corporation (dollars in millions):
		December 31,		September 30,
	Credit Agreement:	2013		2014
	Term Debt - payable to lenders at LIBOR plus applicable margin (1.95% as of September 30, 2014), matures September 17, 2019	$	-	$	225
	Term Debt - payable to lenders at LIBOR plus applicable margin (2.67% as of December 31, 2013), terminated September 17, 2019		231.3
	Revolving Credit Facility payable to lenders, interest at LIBOR plus applicable margin (1.90% as of September 30, 2014), matures September 17, 2019		-		135.9
	Revolving Credit Facility payable to lenders, interest at base rate plus applicable margin (4.75% as of December 31, 2013), terminated September 17, 2019		-		-
	Total debt		231.3		360.9
	Less: Current portion of long-term debt		12.5		2.8
	Total long-term debt	$	218.8	$	358.1
	NOTE 4—CREDIT AGREEMENT (Continued)
Indebtedness Maturities	'
	The Corporation's indebtedness has the following maturities for the remaining life of the Credit Agreement (dollars in millions):
	Year Ending December 31,	Term Debt		Revolving Credit Facility		Total Maturities
	2014	$	-	$	-	$	-
	2015		5.6		-		5.6
	2016		11.3		-		11.3
	2017		11.3		-		11.3
	2018		11.3		-		11.3
	2019		185.5		135.9		321.4
		$	225	$	135.9	$	360.9

RESTRUCTURING_COSTS_AND_OTHER_1

RESTRUCTURING COSTS AND OTHER CHARGES (Tables)	9 Months Ended
	Sep. 30, 2014
RESTRUCTURING COSTS AND OTHER CHARGES [Abstract]	'
Restructuring Liability	'
	The following table presents the components of the Corporation's restructuring liability (dollars in millions):
		Balance at							Balance at
		31-Dec-13		Accrual		Utilized Amounts			30-Sep-14
	Employee Severance and related costs	$	1.8	$	2.1	$	(3.5	)	$	0.4
	Facility costs		0.8		1.1		(0.7	)		1.2
		$	2.6	$	3.2	$	(4.2	)	$	1.6

COMMON_STOCK_PREFERRED_STOCK_T1

COMMON STOCK, PREFERRED STOCK, TREASURY STOCK, STOCK-BASED COMPENSATION AND OTHER BENEFITS (Tables)	9 Months Ended
	Sep. 30, 2014
COMMON STOCK, PREFERRED STOCK, TREASURY STOCK, STOCK-BASED COMPENSATION AND OTHER BENEFITS [Abstract]	'
Stock Option Activity	'
	Stock options were not granted to officers and employees during 2013 or the nine months ended September 30, 2014. The following table summarizes option activity for the periods presented:
		Number of Shares		Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Term		Aggregate Intrinsic Value (in millions)
	Outstanding shares at December 31, 2013	1,289,573		$	14.63	2.9 years		$	8.9
	Exercised	-278,350			14.77
	Canceled	-87,799			12.67
	Expired	-859			14.41
	Outstanding shares at September 30, 2014	922,565		$	14.63	2.3 years		$	9
	Exercisable shares at September 30, 2014	827,016		$	15.06	2.2 years		$	7.7
Nonvested Share Activity	'
	The following table summarizes nonvested share activity for the periods presented:
			Number of Shares			Weighted- Average Grant Date Fair Value
	Outstanding shares at December 31, 2013			1,096,674		$	13.47
	Granted - Restricted Stock Units			196,126			25.58
	Granted - Performance Share Units			247,290			20.01
	Forfeited			(102,591	)		15.67
	Vested			(487,713	)		12.37
	Outstanding shares at September 30, 2014			949,786		$	18

INCOME_TAXES_Tables

INCOME TAXES (Tables)	9 Months Ended
	Sep. 30, 2014
INCOME TAXES [Abstract]	'
Provision for Income Taxes	'
	The provision for income taxes is based upon the Corporation's estimate of annual taxable income or loss for each respective accounting period. The following table summarizes our provision for income taxes for the periods presented (dollars in millions):
		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2014			2013			2014
	Provision (benefit) for income taxes	$	4.2		$	2.2		$	19.3		$	2.9
	Total provision as a percentage of pre-tax income (loss)		NM	*		21	%		57.1	%		45.3	%
	*NM - Not Meaningful

EARNINGS_PER_SHARE_Tables

EARNINGS PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2014
EARNINGS PER SHARE [Abstract]	'
Computation of Basic and Diluted Earnings Per Share	'
	The following table sets forth the computation of basic and diluted earnings (loss) per share (dollars in millions, except per share amounts):
		Three Months Ended September 30,					Nine Months Ended September 30,
		2013			2014		2013		2014
	Numerator:
	Numerator for basic and earnings (loss) per diluted share - net income (loss)	$	-6.2		$	8.5	$	14.5	$	3.6
	Denominator:
	Denominator for basic earnings (loss) per share - weighted average shares		29,655,201			30,073,133		29,645,380		29,944,875
	Effective of dilutive securities (stock options, restricted stock units and performance share units)		-			522,169		304,999		558,053
	Denominator for earnings (loss) per diluted share - adjusted weighted average shares		29,655,201			30,595,302		29,950,379		30,502,928
	Basic earnings (loss) per share	$	-0.21	(b)	$	0.28	$	0.49	$	0.12
	Earnings (loss) per diluted share	$	-0.21	(b)	$	0.28	$	0.48	$	0.12
	Unexercised employee stock options and unvested restricted shares excluded from the effect of dilutive securities above (a)(b)		1,917,486			465,377		2,028,557		481,844
	(a)            These unexercised employee stock options, unvested restricted shares and performance shares that have not yet met performance conditions are not included in the computation of diluted earnings (loss) per share because to do so would be anti-dilutive for the periods presented.
	Stock options and restricted shares and units granted by the Corporation are treated as potential common shares outstanding in computing earnings per diluted share. Performance share units are treated as potential common shares outstanding in computing earnings per diluted share only when the performance conditions are met.
	Common shares repurchased by the Corporation reduce the number of basic shares used in the denominator for basic and diluted earnings (loss) per share.
	(b)            The diluted loss per share for the three months ended September 30, 2013 does not include the effects of potential common shares because its inclusion would be anti-dilutive due to the net loss for the period.
	Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

ORGANIZATION_AND_SUMMARY_OF_SI3

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Additional Information (Details) (USD $)	9 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014
	Segment	OncoMed Speciality, LLC [Member]	Minimum [Member]	Maximum [Member]
	Pharmacy
	Hospital
Property, Plant and Equipment [Line Items]	'	'	'	'
Number of operating institutional pharmacies	104	'	'	'
Number of specialty infusion pharmacies	14	'	'	'
Number of specialty oncology pharmacies	5	'	'	'
Number of states in which there are institutional pharmacies	45	'	'	'
Number of pharmacy management services hospitals	89	'	'	'
Number of operating segments	3	'	'	'
Percentage by which discounted cash flows were greater than current book value (in hundredths)	65.00%	'	'	'
Impairment triggers of goodwill and other intangible assets	$0	'	'	'
Finite-lived intangible assets useful lives	'	'	'5 years	'20 years
Business Acquisition [Line Items]	'	'	'	'
Percentage of ownership acquired (in hundredths)	'	37.50%	'	'

ORGANIZATION_AND_SUMMARY_OF_SI4

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Schedule of Financial Liability Recorded at Fair Value (Details) (Recurring [Member], USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Market Approach [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Deferred Compensation Plan	($7.70)	($6.90)
Income Approach [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Contingent Consideration	-1.8	-0.7
Mandatorily Redeemable Interest	-7.5	-8.2
Level 1 [Member] | Market Approach [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Deferred Compensation Plan	0	0
Level 1 [Member] | Income Approach [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Contingent Consideration	0	0
Mandatorily Redeemable Interest	0	0
Level 2 [Member] | Market Approach [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Deferred Compensation Plan	-7.7	-6.9
Level 2 [Member] | Income Approach [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Contingent Consideration	0	0
Mandatorily Redeemable Interest	0	0
Level 3 [Member] | Market Approach [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Deferred Compensation Plan	0	0
Level 3 [Member] | Income Approach [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Contingent Consideration	-1.8	-0.7
Mandatorily Redeemable Interest	($7.50)	($8.20)

ORGANIZATION_AND_SUMMARY_OF_SI5

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Schedule of Accounts Receivable and Summarized Aging Categories (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Allowance for doubtful accounts	($57.40)	($56.70)	($56.40)
Accounts receivable, net	213.7	199.4	'
0 to 60 days	57.30%	55.50%	'
61 to 120 days	16.90%	18.80%	'
Over 120 days	25.80%	25.70%	'
Total accounts receivable recorded percentage due	100.00%	100.00%	'
Institutional Health Care Providers [Member]	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Accounts receivable, gross	164.2	160.9	'
Medicare Part D [Member]	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Accounts receivable, gross	36.9	31.1	'
Private Payor And Other [Member]	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Accounts receivable, gross	31.3	29.7	'
Insured [Member]	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Accounts receivable, gross	23.1	20	'
Medicaid [Member]	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Accounts receivable, gross	11.7	11.9	'
Medicare [Member]	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Accounts receivable, gross	$3.90	$2.50	'

ORGANIZATION_AND_SUMMARY_OF_SI6

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Schedule of Allowance for Doubtful Accounts (Details) (USD $)	9 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Allowance for Doubtful Accounts Receivable [Roll Forward]	'	'
Allowance for doubtful accounts, Beginning Balance	$56.70	$56.40
Allowance for doubtful accounts, Charges to Costs and Expenses	16.6	22.7
Allowance for doubtful accounts, Write-offs	-15.9	-22.4
Allowance for doubtful accounts, Ending Balance	$57.40	$56.70

ACQUISITIONS_Additional_Inform

ACQUISITIONS, Additional Information (Details) (USD $)	3 Months Ended		9 Months Ended			9 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2013	Sep. 30, 2014
						2014 Acquisitions [Member]	2013 Acquisitions [Member]	2013 Acquisitions [Member]	2013 Acquisitions [Member]	OncoMed Speciality, LLC [Member]	OncoMed Speciality, LLC [Member]
						Facility	Facility		Facility
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Number of Acquisitions Completed	'	'	'	'	'	5	'	'	'	'	'
Number of acquisitions of long-term care businesses completed	'	'	'	'	'	4	'	'	5	'	'
Number of Acquisitions of Infusion Business Completed	'	'	'	'	'	1	'	'	'	'	'
Cash payments for acquisitions	$107.20	$4.10	$124.80	$4.60	'	$114.10	'	'	$25.80	'	'
Cash Payment for acquisitions made during current year	'	'	'	'	'	'	'	'	10.7	'	'
Gain recognized related to acquisitions	-0.1	0	0.2	0	'	'	'	'	'	'	'
Tax deductible goodwill	149.1	'	149.1	'	128.5	29.4	'	'	'	'	'
Contingent payable originating from earnout provisions of acquisition	'	'	'	'	'	1.1	0.7	'	0.7	'	'
Revenues	470.2	436.8	1,371	1,307.40	'	10.5	'	'	'	'	'
Net income	8.5	-6.2	3.6	14.5	'	0.5	'	'	'	'	'
Date of acquisition	'	'	'	'	'	'	'	'	'	6-Dec-13	'
Percentage of issued share capital acquired (in hundredths)	'	'	'	'	'	'	'	'	'	37.50%	'
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	'	'	'	'	'	'	'	'	'	62.50%	'
Purchase price of the acquisition	'	'	'	'	'	'	'	'	'	10.8	'
Recorded goodwill in transaction	'	'	'	'	'	39.5	8	'	8	'	4.6
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount	'	'	'	'	'	'	'	'	'	8.2	7.5
Acquisition costs	'	'	'	'	'	'	'	'	4.9	'	'
Measurement period adjustments	'	'	'	'	'	'	'	0.6	'	'	'
Identifiable intangibles acquired	'	'	'	'	'	$61.40	$10.30	'	$10.30	'	$17.30

ACQUISITIONS_Schedule_of_Purch

ACQUISITIONS, Schedule of Purchase Price Allocation (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Business Acquisition [Line Items]	'	'
Deferred tax assets, net	$38.50	$36.90
Goodwill	321.5	282
Amounts Recognized As Of Acquisition Date [Member]	'	'
Business Acquisition [Line Items]	'	'
Accounts receivable	25.2	'
Inventory	6.9	'
Deferred tax assets, net	3	'
Other current assets	3.1	'
Equipment and leasehold improvements	4.2	'
Other long-term assets	0	'
Deferred tax assets	4.1	'
Identifiable intangibles	61.4	'
Goodwill	39.5	'
Total Assets	147.4	'
Current liabilities	26.4	'
Deferred tax liabilities - long-term	0	'
Other long-term liabilities	6.9	'
Total Liabilities	33.3	'
Total purchase price, less cash acquired	114.1	'
2014 Acquisitions [Member]	'	'
Business Acquisition [Line Items]	'	'
Identifiable intangibles	61.4	'
2014 Acquisitions [Member] | Amounts Previously Recognized As Of Acquisition Date [Member]	'	'
Business Acquisition [Line Items]	'	'
Accounts receivable	25.2	'
Inventory	6.7	'
Deferred tax assets, net	3	'
Other current assets	3.1	'
Equipment and leasehold improvements	4.2	'
Other long-term assets	0	'
Deferred tax assets	4.1	'
Identifiable intangibles	61.4	'
Goodwill	39.7	'
Total Assets	147.4	'
Current liabilities	26.4	'
Deferred tax liabilities - long-term	0	'
Other long-term liabilities	6.9	'
Total Liabilities	33.3	'
Total purchase price, less cash acquired	114.1	'
2014 Acquisitions [Member] | Measurement Period Adjustments [Member]	'	'
Business Acquisition [Line Items]	'	'
Accounts receivable	0	'
Inventory	0.2	'
Deferred tax assets, net	0	'
Other current assets	0	'
Equipment and leasehold improvements	0	'
Other long-term assets	0	'
Deferred tax assets	0	'
Identifiable intangibles	0	'
Goodwill	-0.2	'
Total Assets	0	'
Current liabilities	0	'
Deferred tax liabilities - long-term	0	'
Other long-term liabilities	0	'
Total Liabilities	0	'
Total purchase price, less cash acquired	$0	'

ACQUISITIONS_Schedule_of_Pro_F

ACQUISITIONS, Schedule of Pro Forma Financial Information (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Business Acquisition Pro Forma Information [Abstract]	'	'	'	'
Revenues	$513	$494.90	$1,521.90	$1,484.10
Net income	$5.70	($7.10)	($2)	$12.90
Earnings per common share [Abstract]	'	'	'	'
Basic (in dollars per share)	$0.19	($0.24)	($0.06)	$0.44
Diluted (in dollars per share)	$0.19	($0.24)	($0.06)	$0.43

GOODWILL_AND_INTANGIBLES_Addit

GOODWILL AND INTANGIBLES, Additional Information (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
GOODWILL AND INTANGIBLES [Abstract]	'	'	'	'	'
Carrying amount of goodwill	$321.50	'	$321.50	'	$282
Amortization expense	$4.90	$3.70	$13.60	$11.70	'

GOODWILL_AND_INTANGIBLES_Sched

GOODWILL AND INTANGIBLES, Schedule of Finite Lived Intangible Assets (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
Finite-Lived Intangible Assets [Line Items]	'
Finite Lived Intangible Assets Gross, Beginning Balance	$198.30
Finite Lived Intangible Assets Gross, Additions	61.4
Finite Lived Intangible Assets Gross, Ending Balance	259.7
Accumulated amortization, Beginning Balance	-62
Accumulated amortization, Additions	-13.6
Accumulated amortization, Ending Balance	-75.6
Net intangible assets, Beginning Balance	136.3
Net intangible assets, Additions	47.8
Net intangible assets, Impairments	184.1
Customer Relationships [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Finite Lived Intangible Assets Gross, Beginning Balance	121.2
Finite Lived Intangible Assets Gross, Additions	56.4
Finite Lived Intangible Assets Gross, Ending Balance	177.6
Trade Name [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Finite Lived Intangible Assets Gross, Beginning Balance	60.2
Finite Lived Intangible Assets Gross, Additions	2
Finite Lived Intangible Assets Gross, Ending Balance	62.2
Non-Compete Agreements [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Finite Lived Intangible Assets Gross, Beginning Balance	16.9
Finite Lived Intangible Assets Gross, Additions	3
Finite Lived Intangible Assets Gross, Ending Balance	$19.90

CREDIT_AGREEMENT_Additional_In

CREDIT AGREEMENT, Additional Information (Details) (USD $)	9 Months Ended	12 Months Ended	1 Months Ended	9 Months Ended	1 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013	2-May-11	Sep. 30, 2014	2-May-11	Sep. 30, 2014	2-May-11
			Term Debt [Member]	Term Debt [Member]	Revolving Credit Facility [Member]	Revolving Credit Facility [Member]	Total Debt Capacity [Member]
Line of Credit Facility [Line Items]	'	'	'	'	'	'	'
Credit agreement maximum borrowing capacity	'	'	$225	'	$310	'	$450
Credit agreement outstanding	'	'	'	225	'	135.9	'
Debt instrument maturity date	17-Sep-19	17-Sep-14	17-Sep-19	'	17-Sep-19	'	'
Letters of Credit outstanding	2.5	'	'	'	'	'	'
Total availability under the revolving credit facility	'	'	'	'	'	$171.60	'

CREDIT_AGREEMENT_Schedule_of_T

CREDIT AGREEMENT, Schedule of Term Debt and Revolving Credit Facility (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Line of Credit Facility [Line Items]	'	'
Total debt	$360.90	$231.30
Less: Current portion of long-term debt	2.8	12.5
Total long-term debt	358.1	218.8
Term Debt [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Total debt	225	'
Term Debt [Member] | 2011 Credit Agreement [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Total debt	'	231.3
Term Debt [Member] | 2014 Credit Agreement [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Total debt	225	0
Revolving Credit Facility [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Total debt	135.9	'
Revolving Credit Facility [Member] | 2011 Credit Agreement [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Total debt	0	0
Revolving Credit Facility [Member] | 2014 Credit Agreement [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Total debt	$135.90	$0

CREDIT_AGREEMENT_Schedule_of_T1

CREDIT AGREEMENT, Schedule of Term Debt and Revolving Credit Facility (Parenthetical) (Details)	9 Months Ended	12 Months Ended		1 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2013	2-May-11	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013
			2011 Credit Agreement [Member]	Term Debt [Member]	Term Debt [Member]	Term Debt [Member]	Revolving Credit Facility [Member]	Revolving Credit Facility [Member]
						2011 Credit Agreement [Member]
Line of Credit Facility [Line Items]	'	'	'	'	'	'	'	'
Debt instrument interest rate (in hundredths)	'	'	'	'	1.95%	2.67%	1.90%	4.75%
Debt instrument maturity date	17-Sep-19	17-Sep-14	17-Sep-14	17-Sep-19	'	'	'	'

CREDIT_AGREEMENT_Schedule_of_I

CREDIT AGREEMENT, Schedule of Indebtedness Maturities (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Debt Instrument [Line Items]	'	'
2014	$0	'
2015	5.6	'
2016	11.3	'
2017	11.3	'
2018	11.3	'
2019	321.4	'
Total debt	360.9	231.3
Term Debt [Member]	'	'
Debt Instrument [Line Items]	'	'
2014	0	'
2015	5.6	'
2016	11.3	'
2017	11.3	'
2018	11.3	'
2019	185.5	'
Total debt	225	'
Term Debt [Member] | 2014 Credit Agreement [Member]	'	'
Debt Instrument [Line Items]	'	'
Total debt	225	0
Term Debt [Member] | 2011 Credit Agreement [Member]	'	'
Debt Instrument [Line Items]	'	'
Total debt	'	231.3
Revolving Credit Facility [Member]	'	'
Debt Instrument [Line Items]	'	'
2014	0	'
2015	0	'
2016	0	'
2017	0	'
2018	0	'
2019	135.9	'
Total debt	135.9	'
Revolving Credit Facility [Member] | 2014 Credit Agreement [Member]	'	'
Debt Instrument [Line Items]	'	'
Total debt	135.9	0
Revolving Credit Facility [Member] | 2011 Credit Agreement [Member]	'	'
Debt Instrument [Line Items]	'	'
Total debt	$0	$0

CREDIT_AGREEMENT_Details

CREDIT AGREEMENT (Details)	9 Months Ended
	Sep. 30, 2014
Debt Instrument [Line Items]	'
Letter of credit base rate	0.13%
Interest rate coverage ratio	3
Leverage ratio	3.75
Percent of revenues capital spending limitation (in hundredths)	5.00%
Minimum [Member]	'
Debt Instrument [Line Items]	'
Letter of credit fees floating rate	1.50%
Commitment fee annual percentage	0.25%
Maximum [Member]	'
Debt Instrument [Line Items]	'
Letter of credit fees floating rate	2.25%
Commitment fee annual percentage	0.35%
Base Rate [Member] | Minimum [Member]	'
Debt Instrument [Line Items]	'
Floating Interest rate (in hundredths)	0.50%
Base interest rate (in hundeths)	0.50%
Base Rate [Member] | Maximum [Member]	'
Debt Instrument [Line Items]	'
Floating Interest rate (in hundredths)	1.25%
Eurodollar [Member] | Minimum [Member]	'
Debt Instrument [Line Items]	'
Floating Interest rate (in hundredths)	1.50%
Eurodollar [Member] | Maximum [Member]	'
Debt Instrument [Line Items]	'
Floating Interest rate (in hundredths)	2.25%
Base interest rate (in hundeths)	1.00%

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES, Additional Information (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
	Pharmacy
	Week
	Complaint
	Exclusion
Pending litigation [Line Items]	'
Receivable - ABC litigation	$20.80
Loss Contingencies [Line Items]	'
Number of pharmacies	2
DEA settlement	1
Number of complaints	2
Number of exclusions added to AMP definition	3
Amount accrued for legal actions and investigations	40.1
Weeks of paid vacation per year for executive officers	4
FUL and AMP changes [Member]	'
Loss Contingencies [Line Items]	'
Monthly average manufacturers price (in hundredths)	175.00%
California Medicaid [Member]	'
Loss Contingencies [Line Items]	'
Reimbursement reduction for healthcare providers (in hundredths)	10.00%
Liability recorded representing best estimate of expected amount of recovery	3.3
Quarter 2 PVA claim [Member]	'
Pending litigation [Line Items]	'
Receivable - ABC litigation	8.5
Quarter 3 PVA claims [Member]	'
Pending litigation [Line Items]	'
Receivable - ABC litigation	$12.30

MERGER_ACQUISITION_INTEGRATION1

MERGER, ACQUISITION, INTEGRATION COSTS AND OTHER CHARGES, Additional Information (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
MERGER, ACQUISITION, INTEGRATION COSTS AND OTHER CHARGES [Abstract]	'	'	'	'
Merger, acquisition, integration costs and other charges	$3.80	$1.10	$10.30	$6.60
Integration costs and other charges	0.1	0.1	0.3	2.1
Acquisition costs	$3.70	$1	$10	$4.50

RESTRUCTURING_COSTS_AND_OTHER_2

RESTRUCTURING COSTS AND OTHER CHARGES (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring costs	$0.10	$1	$3.20	$1
Restructuring Reserve [Roll Forward]	'	'	'	'
Beginning Balance	'	'	2.6	'
Accrual	'	'	3.2	'
Utilized amounts	'	'	-4.2	'
Ending Balance	1.6	'	1.6	'
Employee Severance and Related Costs [Member]	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'
Beginning Balance	'	'	1.8	'
Accrual	'	'	2.1	'
Utilized amounts	'	'	-3.5	'
Ending Balance	0.4	'	0.4	'
Facility Costs [Member]	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'
Beginning Balance	'	'	0.8	'
Accrual	'	'	1.1	'
Utilized amounts	'	'	-0.7	'
Ending Balance	$1.20	'	$1.20	'

COMMON_STOCK_PREFERRED_STOCK_T2

COMMON STOCK, PREFERRED STOCK, TREASURY STOCK, STOCK-BASED COMPENSATION AND OTHER BENEFITS, Additional Information (Details) (USD $)	9 Months Ended		1 Months Ended	9 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013	Aug. 31, 2010	Sep. 30, 2014	Jul. 02, 2012	Aug. 31, 2010
			Treasury Stock [Member]	Treasury Stock [Member]	Treasury Stock [Member]	Treasury Stock [Member]
						Maximum [Member]
Class of Stock [Line Items]	'	'	'	'	'	'
Common stock shares repurchase authorized, value	'	'	'	'	$25	$25
Common stock shares repurchased	'	'	10.5	'	'	'
Common stock shares repurchase authorized, value that remains available	'	'	'	19.7	'	'
Aggregate price of shares redeemed	'	'	'	5.1	'	'
Treasury Stock, Value	2,617,305	2,416,971	'	2,617,305	'	'
Vested awards redeemed (in shares)	'	'	'	200,334	'	'
Weighted average remaining term of nonvested shares	'2 years 7 months 6 days	'	'	'	'	'
Intrinsic value of nonvested shares	$23.20	'	'	'	'	'

COMMON_STOCK_PREFERRED_STOCK_T3

COMMON STOCK, PREFERRED STOCK, TREASURY STOCK, STOCK-BASED COMPENSATION AND OTHER BENEFITS, Schedule of Stock Option Activity (Details) (USD $)	3 Months Ended	9 Months Ended	12 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013
Number of Shares [Abstract]	'	'	'
Outstanding, Beginning Balance (in shares)	'	1,289,573	'
Exercised (in shares)	'	-278,350	'
Canceled (in shares)	'	-87,799	'
Expired (in shares)	'	-859	'
Outstanding, Ending Balance (in shares)	922,565	922,565	1,289,573
Exercisable Options at end of year (in shares)	827,016	827,016	'
Weighted Average Exercise Price Per Share [Abstract]	'	'	'
Weighted-Average Exercise Price Per Share, Outstanding, Beginning (in dollars per share)	'	$14.63	'
Weighted-Average Exercise Price Per Share, Exercised (in dollars per share)	'	$14.77	'
Weighted-Average Exercise Price Per Share, Canceled (in dollars per share)	'	$12.67	'
Weighted-Average Exercise Price Per Share, Expired (in dollars per share)	'	$14.41	'
Weighted-Average Exercise Price Per Share, Outstanding, Ending (in dollars per share)	$14.63	$14.63	$14.63
Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)	$15.06	$15.06	'
Weighted Average Remaining Term and Aggregate Intrinsic Value [Abstract]	'	'	'
Weighted-Average Remaining Term, Outstanding, Beginning	'2 years 3 months 18 days	'	'2 years 10 months 24 days
Weighted-Average Remaining Term, Outstanding, Ending	'2 years 3 months 18 days	'	'2 years 10 months 24 days
Weighted-Average Remaining Term, Exercisable	'	'2 years 2 months 12 days	'
Aggregate Intrinsic Value, Outstanding, Beginning	'	$8.90	'
Aggregate Intrinsic Value, Outstanding, Ending	9	9	8.9
Aggregate Intrinsic Value, Exercisable	$7.70	$7.70	'

COMMON_STOCK_PREFERRED_STOCK_T4

COMMON STOCK, PREFERRED STOCK, TREASURY STOCK, STOCK-BASED COMPENSATION AND OTHER BENEFITS, Schedule of Nonvested Share Activity (Details) (USD $)	9 Months Ended
	Sep. 30, 2014
Number of Shares [Abstract]	'
Number of Shares, Outstanding, Beginning (in shares)	1,096,674
Number of Shares, Forfeited (in shares)	-102,591
Number of Shares, Vested (in shares)	-487,713
Number of Shares, Outstanding, Ending (in shares)	949,786
Weighted-Average Grant Date Fair Value	'
Weighted-Average Grant Date Fair Value, Outstanding, Beginning (in dollars per share)	$13.47
Weighted-Average Grant Date Fair Value, Forfeited (in dollars per share)	$15.67
Weighted-Average Grant Date Fair Value, Vested (in dollars per share)	$12.37
Weighted-Average Grant Date Fair Value, Outstanding, Ending (in dollars per share)	$18
Nonvested Restricted Stock Units [Member]	'
Number of Shares [Abstract]	'
Number of Shares, Granted (in shares)	196,126
Weighted-Average Grant Date Fair Value	'
Weighted-Average Grant Date Fair Value, Granted (in dollars per share)	$25.58
Performance Share Units [Member]	'
Number of Shares [Abstract]	'
Number of Shares, Granted (in shares)	247,290
Weighted-Average Grant Date Fair Value	'
Weighted-Average Grant Date Fair Value, Granted (in dollars per share)	$20.01

INCOME_TAXES_Schedule_of_Provi

INCOME TAXES, Schedule of Provision for Income Taxes (Details) (USD $)	3 Months Ended			9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013		Sep. 30, 2014	Sep. 30, 2013
INCOME TAXES [Abstract]	'	'		'	'
Provision for income taxes	$2.20	$4.20		$2.90	$19.30
Total provision as a percentage of pre-tax income (in hundredths)	21.00%	0.00%	[1]	45.30%	57.10%
[1]	NM - Not Meaningful

INCOME_TAXES_Additional_Inform

INCOME TAXES, Additional Information (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Operating Loss Carryforwards [Line Items]	'	'	'	'	'
pmc_IncreaseInTaxProvisionFromNonDeductibleLegalCharges	'	'	$2	$6.60	'
Provision for income taxes as a percentage of pre-tax income before the charge for the legal accrual (in hundredths)	'	'	37.00%	38.10%	'
Tax deductible goodwill	149.1	'	149.1	'	128.5
Deferred tax assets, total	28.6	'	28.6	'	18.2
Valuation allowances	0	'	0	'	'
Settlement Litigation And Other Charges	1.1	17.2	28.9	17.4	'
Minimum [Member]	'	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'	'
Operating loss carryforward period	'	'	'1 year	'	'
Maximum [Member]	'	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'	'
Operating loss carryforward period	'	'	'20 years	'	'
U.S. Federal Tax Jurisdictions [Member]	'	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'	'
Unrecognized tax benefits	0	'	0	'	0
State and Local Jurisdiction [Member]	'	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'	'
Net operating loss carryforwards	7.2	'	7.2	'	'
Valuation allowances	4.1	'	4.1	'	'
State and Local Jurisdiction [Member] | Minimum [Member]	'	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'	'
Statute of limitations for tax examinations	'	'	'3 years	'	'
State and Local Jurisdiction [Member] | Maximum [Member]	'	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'	'
Statute of limitations for tax examinations	'	'	'5 years	'	'
2013 Acquisitions [Member]	'	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'	'
Net operating loss carryforwards	5.2	'	5.2	'	'
Tax benefit from net operating loss carryforwards	1.8	'	1.8	'	'
2014 Acquisitions [Member]	'	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'	'
Net operating loss carryforwards	24.8	'	24.8	'	'
Tax benefit from net operating loss carryforwards	$8.70	'	$8.70	'	'

EARNINGS_PER_SHARE_Schedule_of

EARNINGS PER SHARE, Schedule of Computation of Basic and Diluted Earnings Per Share (Details) (USD $)	3 Months Ended				9 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2014		Sep. 30, 2013		Sep. 30, 2014	Sep. 30, 2013
Numerator: [Abstract]	'		'		'	'
Numerator for basic and earnings per diluted share - net income	$8.50		($6.20)		$3.60	$14.50
Denominator: [Abstract]	'		'		'	'
Denominator for basic earnings per share - weighted average shares (in shares)	30,073,133		29,655,201		29,944,875	29,645,380
Effective of dilutive securities (stock options, restricted stock units and performance share units) (in shares)	522,169		0		558,053	304,999
Denominator for earnings per diluted share - adjusted weighted average shares (in shares)	30,595,302		29,655,201		30,502,928	29,950,379
Basic earnings per share (in dollars per share)	$0.28		($0.21)		$0.12	$0.49
Earnings per diluted share (in dollars per share)	$0.28		($0.21)		$0.12	$0.48
Unexercised employee stock options and unvested restricted shares excluded from the effect of dilutive securities above (a) (in shares)	465,377	[1]	1,917,486	[1]	481,844	2,028,557
[1]	These unexercised employee stock options, nonvested restricted shares and performance shares that have not yet met performance conditions are not included in the computation of diluted earnings per share because to do so would be anti-dilutive for the periods presented.